The Identification of Cooperating Mutations in TAL1-Mediated Leukemia in the Mouse: A Dissertation by Calvo, Jennifer Ann
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2005-09-01 
The Identification of Cooperating Mutations in TAL1-Mediated 
Leukemia in the Mouse: A Dissertation 
Jennifer Ann Calvo 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Amino Acids, Peptides, and Proteins Commons, Animal Experimentation and Research 
Commons, Genetic Phenomena Commons, and the Neoplasms Commons 
Repository Citation 
Calvo JA. (2005). The Identification of Cooperating Mutations in TAL1-Mediated Leukemia in the Mouse: 
A Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/987p-s242. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/20 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
A Dissertation Presented
Jennifer Ann Calvo
Submitted to the Faculty of the
University of Massachusetts Graduate School of Biomedical Sciences, Worcester
In partial fulfllment of the requirements for the degree of
DOCTOR OF PHILOSOPHY
2005

Acknowledgements
I would like to than my mentor, Michelle Kellher, for her guidance and support
throughout my graduate career. I also appreciate the support, advice and criticism of my
committee members, Lucio Castila, Stephen Jones, Rachel Gerstein, Timothy Kowalik
and Barbara Osborne. I am also grateful to the members of the Kellher lab for their
support, encouragement and helping to provide a wonderful working environment.
would like to thank Leslie Cuningham for contributing the MoML V RIM experiment
(Figue 16), Veena Krshnamoorthy for contributing the DAPT -sensitivity assay (Figure
17B and 18A). Additionally, I would like to than Jennifer O'Neil for performing the
Notch mutational analysis (Table 3). I would like to thank the UMass Transgenic Anmal
Modeling Core for their generation of mice for this work.
We appreciate the generosity of Dr. Jos Domen from Duke University who
provided us with the H2K-Bcl- transgenic mice, Dr. Anthony Capobianco of The Wistar
Institute for providing us with the EJ1tTA/Notch transgenic mice, and Dr. Dean Felsher
from Stanford University for the EJ1tTA/Myc transgenic mice. I would like to thank Dr.
Naomi Rosenberg from Tufts University for providing the MoML V and p16 cDNA
probe. Additionally, I also want to than Dr. Manoj Bhasin, from Dana Farber Cancer
Institute for assistance in the microaray analysis.
I also want to thank my parents and husband for their overwhelming support
encouragement and love. I am extremely grateful and could not have done this without
you.
Abstract
sequential series of mutational events is necessary for the development of
leukemia. The misexpression of TALI , a basic helix-loop-helix (bHLH) transcription
i..
factor, is the most common mutation in T cell acute lymphoblastic leukemia (T-ALL).
Tall transgenic mice develop leukemia with a long latency and incomplete penetrance
indicating additional mutations are necessary to develop disease. To investigate
additional mutational events that potentially contribute to TALI-expressing T-ALL
patients, we sought to identify cooperating mutations in tall transgenic mice. Clinical
studies implicated the loss of the INK4a/ARF locus, which encodes two tuor
suppressors , p16INK4a and p14ARF, in the majority of T-ALL patients. We demonstrated
disease acceleration in tall/ink4a/arf+/-, tall/p16ink4a
+/- 
and tall/pl rf+/- mice , thereby
providing genetic evidence that Tall cooperates with loss of either p16
Ink4a or p19Ar in
leukemogenesis. The cooperation of Tall with the loss of p l6Ink4a or p 19Arf, is consistent
with our observation that Tall alters cell cycle regulation in leukemia by promoting S
phase induction and apoptosis in vivo.
An additional mutational event common in tall tuors is activation of the Notchl
signaling pathway. We provide evidence that the majority of tall tuors express
increased levels of Notchl , and exhibit activating notchl mutations. Additionally, tall
tuors display sensitivity to the pharmacologic inhibition of y-secretase activity in vitro
indicating that y-secretase inhibitors may prove an efficacious treatment for TALl-
expressing T-ALL patients. Furthermore , we developed a doxycycline-regulated Notch
ALL cell line, which wil allow the identification of important Notch 1 IC target genes in
leukemogenesis.
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CHAPTER 
INTRODUCTION
Leukemia/lymphoma is cancer of the blood-forming tissues or the lymphatic
system, afficting approximately 95 000 people anually (American Cancer Society,
2004). It is a heterogeneous disease caused by a multiple genetic abnormalities:
chromosomal translocations, deletions, or mutations. Nonrandom chromosomal
trans locations and inversions are observed in over 65% of acute leukemias (Look, 1997).
One mechanism translocations induce leukemia is through proto-oncogene activation.
This occurs when a proto-oncogene is juxtaposed to either the T cell receptor (TCR)
locus or the immunoglobulin (Ig) locus, resulting in deregulated expression of the
oncogene. Another way chromosomal translocation induces leukemia is through the
formation of chimeric fusion genes; two genes disrupted by the translocation fuse to
encode a chimeric protein with unique properties. The modular structue of transcription
factors faciltates the formation of fuctional chimeric transcription factors such as E2A-
PBXl , AML-ETO, and E2A-HLF.
Leukemogenesis is a multi-step process in which multiple mutations occur to
deregulate pathways essential for proliferation, differentiation, surival , or self-renewal.
Often times the fusion oncoproteins are considered the initiating mutation, being
necessary but not sufficient to induce leukemia. The acquirement of additional
cooperating mutations allows the progression to acute leukemia. Consistent with this,
chromosomal translocations occur in utero (McHale et aI. , 2003; Mori et aI. , 2002), but
childhood acute lymphoblastic leukemia (ALL) does not develop until years later
indicating additional mutations are essential for leukemogenesis. The cooperating
mutations often fuction to enhance proliferation, surival or self-renewal capabilities.
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One common event in leukemogenesis is the inactivation of the basic helix-Ioop-
helix (bHLH) protein, E2A. Two nonrandom translocations, t(1;19)(q23;p13) and
t(17;19)(q23;p13.3), and more recently the inversion, inv(19)(p13;q13), has been shown
to disrupt the E2A locus and result in 25% of B cell acute lymphoblastic leukemia (B-
ALL) (Brambilasca et aI. , 1999; Hunger et aI. , 1992; Inaba et aI. , 1992; Mellentin et aI.
1989). In addition, E2A is fuctionally inhbited by the misexpression of TALI or other
bHLH proteins in the thymus in the majority of T cell acute lymphoblastic leukemia (T-
ALL) (Bash et aI. , 1995).
HLH proteins
Helix-loop-helix proteins (HLH) are a family of evolutionarily-conserved
transcription factors important for various developmental processes such 
hematopoesis , myogenesis , neurogenesis , and pancreatic development (Bain et aI., 1994;
German et aI., 1991; Olson, 1990). The conserved HLH strctue consists of two
amphipathic alpha helices separated by a flexible loop structue that fuctions as a
protein dimerization domain (Mure et aI., 1989). Basic residues adjacent to the HLH
domain confer DNA-binding ability (Ellenberger et aI. , 1994). HLH proteins have been
recently categorized into 6 classes based on expression profies and the ability to
dimerize and bind DNA (Massari and Mure , 2000). Class I HLH proteins , or E proteins
are widely expressed and bind DNA as homodimers or as heterodimers with class II HLH
proteins. They induce transcription through two separable transcription activation
domains , AD! and LH (Aronheim et aI. , 1993; Quong et aI. , 1993). Conversely, class II
HLH proteins are expressed in a tissue-specific manner and bind DNA only as a
heterodimer with E proteins. Class V HLH proteins, or Id proteins, are negative
regulators of either class I or II HLH proteins. They contain a HLH domain but lack a
fuctional DNA-binding domain. Therefore, they fuction as dominant-negative factors
forming heterodimers with both class I and class II HLH proteins, sequestering them into
nonfnctional complexes (Benezra et aI. , 1990; Jen et aI., 1992; Kreider et aI., 1992;
Riechmann et aI. , 1994). This focus ofthis thesis is to determine how the inhibition ofE
proteins , either though structual disruption by the t(I7;19) translocation, or fuctional
disruption by the misexpression of TALI , induces leukemia.
E2A
E2A, a member of the class I HLH proteins , was originally identified through its
ability to bind to E-boxes (CANNTG) within the immunoglobulin enhancer regions
(Henthorn et aI. , 1990; Mure et aI., 1989). The E2A gene encodes two proteins, E12 and
E47, which are alternative spliced gene products and differ only in the exon encoding the
bHLH domain (Sun and Baltimore, 1991). E proteins, which consist of E2A, HEB , and
E2- , are widely expressed proteins. E proteins form heterodimers with class II bHLH
proteins such as, Tall , NeuroD/Beta2, MyoD, and Myogenin, and are essential for
various developmental processes, such as regulation of hematopoesis , myogenesis , and
neurogenesis (Bain et aI. , 1994; Lee et aI. , 1995; Lemercier et aI. , 1997). For example
E proteins form heterodimers with the pancreatic-specific class II HLH transcription
factor, Beta2, to regulate gene expression of a and p cells within the pancreas (Nelson et
aI., 1990). Furhermore beta2 null mice exhibit an extreme reduction of insulin-
producing p cells and become severely diabetic (Naya et aI. , 1997). Similarly, in skeletal
.i!
muscle cells, E47 forms heterodimers with myogenic regulatory factors (M) 
regulate myogenesis (Olson, 1990). Furhermore, the regulation of many class II bHLH
proteins such as, Mashl , Mathl , Neurogenin, and NeuoD by E proteins is essential for
proper neurogenesis (Ben-Arie et aI. , 1997; Guilemot et aI. , 1993; Ma et aI. , 1996). The
importance of E proteins to multiple developmental processes is underscored by the
postnatal lethality observed in mice deficient for E2A, HEB , or E2-2 (Bain et aI., 1994;
Bardt et aI. , 1999; Zhuang et aI. , 1996).
Lymphoid Development
The stages of thymocyte matuation are determined by expression of the co-
receptors, CD4 and CD8 (reviewed in (Zuniga-Pflucker and Lenardo, 1996)). Immatue
thymocytes lack both CD4 and CD8 , and are classified as double negative (DN) cells
which can be fuher subdivided by expression of CD44 and CD25 into 4 stages: DNl
DN2 , DN3 , and DN4. Following productive TCRB rearangement, signaling though the
pre- TCR complex allows the surival, proliferation, and matuation into CD4+ CD8+
double positive (DP) thymocytes. During the DP stage of matuation, thymocytes
rearrange the TCRa chain to form a aB TCR, and following positive and negative
selection, differentiate into either matue CD4+ single positive (SP) or CD8+ SP cells.
Similarly, B lymphocyte development depends on rearrangement and expression
of immunoglobulin genes , and also requires expression of factors, E2A, EBF, IL7R, and
Pax-5 (reviewed in (Hardy and Hayakawa, 2001)). The expression of a productively
rearanged heavy-chain immunoglobulin on the cell surace indicates the transition of
pro-B cell to pre-B cell. Pre-B cell receptor (pre-BCR) signaling results in proliferation
IgH alleleic exclusion, and IgL chain gene rearrangement. Following expression of the B
cell receptor (BCR) on the cell surace, the immatue B lymphocytes undergo selection or
optimal antigen binding, and suriving matue B cells migrate to the periphery.
E2A and Hematopoesis
E proteins are essential for proper development of both B and T lymphocytes
(Bain et aI. , 1997; Bain et aI. , 1994; Zhuang et aI., 1994). In contrast to other tissues
where E proteins fuction as heterodimers with class II HLH proteins , in lymphoid cells
E proteins bind DNA as homodimers. In B lymphocytes , a unque from ofE2A exists: an
E47 homodimer fuctions to induce expression of genes important in differentiation, such
as EBF , Pax- , Ragl and IL7Ra (Kee and Murre, 1998; Mure et aI. , 1991; Shen and
Kadesch, 1995). The unique existence of fuctioning E47 homodimers in B cells has
been suggested to be due to the phosphorylation status of E2a or the presence of an
intermolecular disulfide bond (Markus and Benezra, 1999; Sloan et aI. , 1996).
The importance of E2a in B cell development was first ilustrated through the
targeted disruption of the e2a allele. E2a null mice exhbit a complete block in B lineage
differentiation prior to Ig heavy chain (DwJH) rearrangement (Bain et aI. , 1994; Zhuang
et aI., 1994). In addition e2a-
/- 
mice lack the expression of lymphoid regulatory
transcripts Pax- , A5 , CDI9, mb-l and Rag- l (Bain et aI. , 1994; Zhuang et aI., 1994).
Furhermore , transgenic mice overexpressing the negative regulator of E proteins, Idl
exhibit aB cell differentiation arrest, further confirming the essential role of E2a in B cell
development (Sun, 1994). E2a has been demonstrated to be essential for various stages
of B cell development. For example , E2a is implicated in the regulation of the
rearangement of both Ig heavy and light chains, perhaps though induction of Ragl/2
(Kee and Mure , 1998; O'Riordan and Grosschedl , 1999). Furhermore , E2a expression
is essential to promote Ig class switch recombination upon B cell activation (Quong et aI.
1999). Expression of E2a must be tightly regulated; ectopic expression of E2a is capable
of inappropriately promoting Ig gene rearangement and inducing transcription of Rag 1
A5, IL7- , EBF , TdT, and Pax5 in several cell lines (Choi et aI. , 1996; Kee and Mure
1998; Schlissel et aI. , 1991). Although E47 binds DNA as homodimers in B cells, other
members of the E protein family, E2-2 and Heb, also contribute to B cell development.
Investigation of fetal liver cells from e2-2- and heb-deficient mice , or e2a/e2- , e2a/heb,
e2-2/heb transheterozygote mice reveals drastic decreases in pro-B cells (Zhuang et aI.
1996).
Similarly, in T lymphocytes, E47/HEB heterodimers bind DNA and induce genes
important for differentiation at various stages of thymocyte development. F or example
E4 7/Heb heterodimers bind to E boxes in the regulatory regions and induce transcription
of CD4 and preTa in thymocytes (Sawada and Littman, 1993; Takeuchi et aI. , 2001).
Accordingly, e47 and heb-deficient thymocytes show reduced levels of CD4 and preTa
expression (Tremblay et aI. , 2003; Zhuang et aI. , 1996). The importance ofE proteins in
thymocyte development was further elucidated by the reduced thymocyte cellularity and
the thymocyte differentiation arrest in e2a- heb- or e47- deficient mice (Bain et aI. , 1997;
Bain et aI. , 1999; Bardt et aI. , 1999). E2a deficient mice display dramatically reduced
numbers of total thymocytes , and decreases in both DN and DP cells , and a subsequent
increase in CD8+ SP , and CD4+ SP cells (Bain et aI. , 1997). E47 deficient mice display
an equivalent thymocyte differentiation arest, resulting from a decreased surival of 
cells and enhanced positive selection to both class I and class II-restricted T cell receptors
(Bain et aI. , 1999). Additionally, e2a deficient thymocytes demonstrate an arrest at the
most immatue DNI stage (CD44+CD25-) (Bain et aI. , 1997). This complex thymocyte
arest ilustrated E2a functions durng multiple stages of thymocyte development
including DN development and p-selection. Moreover, E2a is implicated during y8
thymocyte development; e2a deficient mice demonstrate a drastic reduction of 
y/8 
lymphocytes, ilustrating E2a is a critical regulator ofy and 8 V(D)J rearangement (Bain
et aI. , 1999).
In addition to regulating lymphocyte differentiation, E2a may also fuction to
maintain lymphocyte viability. For example , inhibition of E2a by expression of Id3 in
primar B lymphocyte progenitors induces apoptosis, suggesting E2a is required to
maintain the viability of lymphocyte progenitors (Kee et aI. , 2001). Furhermore e47-
DN thymocytes displayed increased levels of apoptosis in vivo and following a 24h
cultue in vitro (Kee et aI., 2002). However, Bcl-2 is unable to rescue these
lymphopoietic defects observed in e47-
/- 
mice, again indicating E47 does not solely
maintain survival of lymphocytes , but also has additional roles during lymphopoesis (Kee
et aI. , 2002).
E2a may fuction in the fate decision of a common lymphoid progenitor towards
B cell development at the expense of natual kiler cells (N) and dendritic cells (DC). A
downegulation of E2a and subsequent upregulation of Id2 occurs durng 
differentiation (Hacker et aI. , 2003), and expression of Id3 in fetal liver organ cultues
(FTOC) resulted in an inhibition of T cell development, and an enhancement of in NK
cells development (Heemskerk et aI., 1997). However e2a /- bone marow derived
cells are plurpotent and can differentiate into dendrtic, NK, myeloid, and T lineages, but
not B lymphocytes in vitro and following reconstitution of lethally-irradiated recipients
(Ikawa et aI. , 2004). This suggests that E2a is absolutely essential for formation of B
lymphocytes , but may not be essential for development of other' hematopoetic lineages.
Functional redundancy amongst E proteins may explain this occurence; Heb and E2-
may compensate for the absence of E2a and allow development of dendrtic, NK,
myeloid and T cell lineages.
E2a and leukemia
The majority of e2a-deficient mice that surive the common postnatal lethality
develop T cell lymphomas with a mean latency of 150 days (Bain et aI. , 1997). E47-
mice do not suffer from postnatal lethality, but nonetheless develop thymomas with a
mean latency of 123 days (Bain et aI., 1997). Therefore, E2a has been speculated to
fuction as a lymphoid-specific tuor suppressor. Consistent with this, transgenic
overexpression of proteins that inhibit E2A fuction, such as Id proteins and Tall , also
induces leukemia in mice (Kelliher et at. , 1996; Kim et aI. , 1999; Morrow et aI., 1999).
Another protein overexpressed in leukemic patients , NOTCH 1 , has also been shown to
inhbit E2A activity although this mechanism has not been fully elucidated (Nie et aI.
2003; Ordentlich et aI. , 1998; Talora et aI. , 2003).
Disruption of the e2a gene is also observed in thee chromosomal translocations
displayed in human leukemic patients. The t(17;19)(q22;p13) and t(I;19)(q23;p13)
translocations generate the chimeric transcription factors, E2A-HLF and E2A-PBX1
respectively (Inaba et aI. , 1992; Mellentin et aI., 1989). These translocations fuse the
transactivation domains of E2A to the DNA-binding domain and protein dimerization
domain of either hepatic leukemia factor (HLF) or pre-B cell leukemic homeoboxl
(PBXl), yielding novel transcription factors. The leukemogenic fuction of these
chimeric transcription factors has been demonstrated though in vitro transformation
assays , bone marow transplantation assays , and transgenic mouse models (Honda et aI.
1999; Kamps and Baltimore , 1993; Monica et aI., 1994; Smith et aI. , 2002; Smith et aI.
1999; Sykes and Kamps, 2004; Yoshihara et aI., 1995). In addition, the crytic
inv(l9)(p13;q13) also disrupts the E2A locus, resulting in the fusion protein E2A-FBI
(Brambilasca et aI. , 1999). Therefore , preferential disruption of E2A either fuctional or
genetic inactivation, suggests that E2A inactivation contrbutes to leukemogenesis.
E2A-HLF
E2A-HLF is a chimeric transcription factor arsmg from a chromosomal
translocation, t(17;19)(q22;p13), observed in 1% of acute pro-B cell ALL (Inaba et aI.
1992; Raimondi et aI. , 1991). The fusion creates a chimeric transcription factor placing
the bZIP domain of HLF under control of the E2A promoter. There are two documented
types of translocations , depending on the breakpoint within the E2A locus; both result in
the fusion of the two transactivation domains of E2A to the DNA-binding and protein
dimerization domains of HLF (Hunger et aI. , 1994). Both translocations conserve the
reading frame of HLF , often times through an unique insertion of intronic DNA, and
nontemplated nucleotides (Hunger et aI. , 1994; Inaba et aI., 1992). This strict
conservation of the reading frame of HLF suggests that the bZIP domain of HLF provides
some leukemogenic fuction to the fusion protein.
HLF is a member of proline and acidic amino acid rich (PAR) subfamily of basic
leucine-zipper (bZIP) transcription factors, which include thyrotroph embryonic factor
(TEF) and albumin promoter D-box binding protein (DBP) (Fonjallaz et aI., 1996).
These PAR bZIP transcription factors are circadian clock output regulators expressed in a
cyclic maner in the suprachiasmatic nucleus (Fonjallaz et aI. , 1996). Interestingly,
recent microaray experiments indicate HLF expression is induced in hematopoetic stem
cells(HSC) (Georgantas et aI., 2004; Ivanova et aI., 2002; Shojaei et aI., 2005).
Furermore , HLF confers repopulating capacity to human hematopoetic stem cells by
inducing BCL-2 expression to inhbit apoptosis (Shojaei et aI. , 2005). Although, HLF is
normally highly expressed in liver, lung and central nervous system, the chromosomal
translocation to the E2A locus , results in the misexpression of the bZIP domain ofHLF 
the lymphoid lineages (Hitzler et aI. , 1999; Hunger et aI. , 1992; Inaba et aI. , 1992).
E2A-HLF expression has been reported to be anti-apoptotic in multiple in vitro
systems. E2A-HLF inhbited apoptosis in IL-3 dependent cells following cytokine
withdrawal, and expression of a dominant-negative E2A-HLF induces apoptosis in
leukemic cells expressing E2A-HLF (Inaba et aI., 1996). In addition, E2a-Hlf abrogates
p53-mediated apoptosis in the myeloid leukemic cells (Altua et aI. , 1998). Furhermore
HLF expression induced BCL-2 expression in HSC , thereby inhbiting apoptosis (Shojaei
et aI. , 2005). The mechanism by which E2A-HLF inhibits apoptosis is predicted by the
similarity between the bZIP domain ofHLF and the bZIP domain of a C.elegans protein
CES-2 (Horvitz, 1999). CES-2 fuctions in a cell death specification pathway, ultimately
inducing the death of two neurosecretory motor neurons (NSM) during nematode
embyogenesis (Ells and Horvitz, 1991; Metzstein et aI., 1996). CES-2 functions as a
negative regulator of CES-l (Ells and Horvitz, 1991), inhbiting apoptosis by interfering
with the fuction ofEGL- l (homolog ofBH3-onIy protein) (Conradt and Horvitz, 1998;
Ells and Horvitz, 1991). Interestingly, in a human t(I7;19) leukemic cell line , E2A-HLF
expression induced the expression of SLUG, a CES- l homolog (Horvitz, 1999; Inukai et
aI., 1999). Therefore , it has been proposed that E2A-HLF expression may contrbute to
leukemogenesis by interfering with this evolutionarily conserved cell death pathway
(Figure 1).
Consistent with the association of the t(I 7; 19) translocation and B-ALL
expression of E2A-HLF induces transformation in various experimental settings.
Expression of E2A-HLF in NIH3T3 cells induces anchorage-independent growth, which
depends on both the transactivation domains of E2A and the bZIP domain of HLF
(Y oshihara et aI. , 1995). Furhermore , expression of E2A-HLF cooperates with BCL-
expression in the transformation of primary bone marow cells (Smith et aI. , 2002).
Additionally, two transgenic mouse models expressing E2a-Hlf using lymphoid-specific
promoters exhibit differentiation arrest of lymphoid cells and develop T cell leukemia
(Honda et aI. , 1999; Smith et aI. , 1999).
E2A disruption occurs in another nonrandom translocation, t( 1; 19), which results
in a similar chimeric transcription factor, E2A-PBXl. Expression of E2A-PBXl is
observed in 20% of pre-B ALL (LeBru and Clear, 1994; Lu et aI. , 1994; Wiliams et
aI. , 1984), activates expression of HOX/BXl target genes in lymphoid cells (Kamps et
aI. , 1996; Lu and Kamps , 1997), and transforms multiple cell tyes in vitro (Kamps et aI.
1991; Kamps and Wright, 1994). Additionally, e2a-pbxl transgenic mice develop T cell
leukemia (Kamps and Baltimore, 1993) and a bone marow reconstitution model develop
myeloid leukemias (Monica et aI. , 1994).
Tall
The TALI gene (also known as SCL and TCL5) encodes a 42 kD class II bHLH
transcription factor. In addition, the allele also encodes a trcated 22kDa isoform
which lacks the transactivation domain (Cheng et aI., 1993), and results from the
translational initiation at an internal methionine. Tall is normally expressed during
murne development at embryonic day 7. 5 (E7.5) in both embryonic and extraembyronic
tissues , and in adult mice in myeloid and eryoid lineages , as well as , megakaryocytes
and mast cells (Begley et aI. , 1989; Green and Begley, 1992; Kallanpur et aI., 1994;
Mouthon et aI. , 1993; Visvader et aI., 1991). In addition, high Tall expression 
observed in all murine and human eryhroid cell lines (Aplan et aI. , 1992; Visvader et aI.
1991). In addition to hematopoetic tissues, Tall is also observed in the central nervous
system , and endothelial lineages (Kallanpur et aI. , 1994).
Tall fuctions during eryhroid and megakaryocyte differentiation. Specifically,
ectopic expression of TAL 1 enhanced erythroid differentiation in leukemic cell lines
(Hoang et aI., 1996), and increased erythroid and megakaryocytic differentiation in
human hematopoietic CD34( + )cells (Elwood et aI., 1998). In addition, Tall expression
increased upon differentiation of murine eryhroleukemia (MEL) cells (Green et aI.
1991) . Moreover antisense Tall prevented eryhroid differentiation in MEL cells
(Aplan et aI., 1992). However, another Tall antisense experiment showed an induction
of eryhroid differentiation in human erythroleukemic cells (Green et aI. , 1991). During
eryoid differentiation, Tall induces transactivation of genes involved in eryoid 
megakarocytic differentiation as par of a multi-protein complex containing E2A
LM02, Ldbl and GAT A 1 (Valge-Archer et aI., 1994; Wadman et aI., 1997).
Recruitment of transcriptional co activators p300 (Huag et aI. , 1999), and PICAF (Huang
et aI., 2000), or corepressor mSin3A (Huang and Brandt, 2000) regulate transcription.
Targeted gene disruption demonstrated Tall is essential for embryonic
hematopoesis. Tall deficient mice are embryonic lethal at E(8. 10), and completely
lack blood and yolk sac hematopoesis (porcher et aI., 1996; Robb et aI., 1995).
Furhermore tall-
/- 
ES cells are unable to differentiate into eryhroid or myeloid lineages
in vitro or in vivo and are unable to produce B or T cells in a rag- deficient blastocyst
complementation assay (porcher et aI., 1996). Together this suggests that Tall is
essential for development of all hematopoietic lineages. However, conditional disruption
of Tall in adult mice indicated continuous Tall expression is essential for proper
differentiation of eryhroid and megakaryocytic precursors, but is dispensable for
myeloid, lymphoid lineages, and the fuction of hematopoetic stem cells (HSCs) (Hall et
aI. , 2003; Mikkola et aI. , 2003).
Transgenic rescue of hematopoetic defects in Tall null embryos by expression of
Tall under control of the gatal promoter revealed an additional function for Tall 
angiogenesis (Visvader et aI., 1998). Although embryonic hematopoesis is rescued
completely, the tall- /gatal- tall transgenic mice stil display embryonic lethality at
E(9.5), dlle to severe angiogenic defects in the yolk sac , including a complete absence of
vitellne vessels (Visvader et aI. , 1998). This role for Tall in angiogenesis is consistent
with the expression of Tall in endothelial cells in the blood island E(8.5), the kidney, and
the lung E(13. 15.5) (Bash et aI., 1995).
Tall fuctions both in the development of hematopoetic and endothelial
angiogenesis suggesting it may fuction in hemangioblasts, a precursor of both
hematopoetic and endothelial lineages. Consistent with this, Tall expression rescues
both hematopoetic and endothelial defects in zebrafish cloche mutant embryos(Liao et
aI. , 1998), and Tall expression partially rescued the hem angioblast defect of flkl-
embryoid bodies in vitro (Ema et aI. , 2003). Although endothelial cells develop normally
in Tall null mice (Visvader et aI., 1998), this data demonstrates that Tall has essential
functions in both hematopoesis and angiogenesis.
Tall and Leukemia
Tall is the most commonly misexpressed oncogene in human T-ALL patients; it
is observed in over 60% ofT-ALL patients (Begley et aI. , 1989). TALI was originally
identified through its involvement in the t(I;14)(p33;qll) translocation, which juxtaposed
TALI to the TCR8 chain (Aplan et aI. , 1990; Begley et aI. , 1989; Brown et aI., 1990).
Since then, it has also been shown to be disrupted in a t(I ;7)(P32;q35) translocation
which juxtaposed TALI to the TCR locus (Fitzgerald et aI. , 1991). The presence of
nontemplated nucleotides and V(D)J signal sequences indicate that ilegitimate V(D)J
recombination may generate these translocations, consistent with the transcriptional
activity of the tall locus at the initiation of RAG activity (Api an et aI. , 1990; Herblot et
aI., 2000). Additional T :-ALL patients display a 90kb intergenic deletion, which places
TALI under control of the SIL promoter (Aplan et aI., 1991; Bash et aI., 1995).
Furhermore , many T -ALL patients display an increase of TAL 1 levels without evidence
of translocation or deletion (Bash et aI., 1993). Increased TALI expression has been
suggested to be due to mutations in either cis-acting regulatory sequences or 
trans-acting
regulatory factors (Bash et aI. , 1995; Ferrando et aI. , 2004). Additionally, L YLl and
T AL2, two proteins sharing significant similarty to the bHLH region of TAL 1 , are also
found disrupted in translocations in T-ALL patients (Mellentin et aI. , 1989; Xia et aI.
1991).
Transgenic mice mimicking Tall misexpression in the thymus, which express tall
under control of the thymus-specific proximal- lck promoter, develop leukemia
(Condorell et aI. , 1996; Kellher et aI. , 1996). These mice develop T cell malignancies
with an incomplete penetrance and a long latency of disease, indicating additional
mutations are required for leukemogenesis. However, other groups developed CD2-Sra-
tall , Ly-6E.l- tall, and pSIL/tall transgenic mice , which do not develop leukemia on a
wild type background (Aplan et aI. , 1997; Goardon et aI. , 2002; Robb et aI. , 1995). The
discrepancy between the phenotypes observed in the tall transgenic models is likely due
to expression of the trans gene during the appropriate stage(s) ofthymocyte development
but may also be explained by trans gene copy number, or trans gene expression levels.
Lck- tall transgenic mice demonstrated a thymocyte differentiation arest, and
27% of mice develop T -ALL with a median surival of 350 days (Kellher et aI. , 1996).
This long latency of disease and low penetrance indicated additional mutations are
required for leukemogenesis. Transgenic anmals expressing a DNA-binding domain
mutant lck-tall (R188G, R189G) mice , also exhibit a thymocyte differentiation arrest, and
develop T cell malignancies, demonstrating a functional DNA-binding domain is not
essential for leukemia, and suggests that Tall may contribute to leukemia by inhbiting
E2A activity. Consistently, the tall/heb+/- and tall/e2a+/- mice exhibit severely
pertbed thymocyte development, decreased expression of E47/Heb target genes , and
disease acceleration (O'Neil et aI. , 2004).
Id proteins
There are 4 members of the inhibitor of differentiation/NA binding (Id) proteins
(Idl-Id4), which are classified as class V bHLH proteins (Massari and Mure , 2000;
Riechman et aI., 1994). Id proteins are widely expressed and form heterodimers with
class I and class II bHLH proteins in vitro and in vivo (Benezra et aI. , 1990; Jen et aI.
1992; Kreider et aI. , 1992; Riechmann et aI. , 1994). Since Id proteins lack a basic DNA-
binding domain, they form fuctionally inert heterodimers (Benezra et aI. , 1990). Id
proteins are highly expressed in proliferative cells , and inhibit differentiation in various
tissues, by inhibiting bHLH proteins (Atherton et aI., 1996; Desprez et aI., 1995;
Melnikova and Chrsty, 1996; Shoji et aI. , 1994). Id transgenic mice verified the role of
Id proteins as inhbitors of E proteins. Lck- idl and Ick- id2 mice demonstrate reduced
thymic cellularity, and substantial T-cell developmental defects , more similar to what is
seen in e2a null mice or tall transgenic mice (Chervinsky et aI. , 1999; Kim et aI. , 1999;
Morrow et aI. , 1999; O'Neil et aI. , 2004). However, the thymocyte differentiation arest
in Idl transgenic mice is more severe compared to E2a null mice, consistent with Id
proteins inhibiting not only E2a, but also Heb and E2-2. Similarly, transgenic mice
expressing Idl in B lymphocytes display a complete lack of B cells, an equivalent
phenotype to that observed in e2a null mice (Sun, 1994). Consistent with Id proteins
inhbiting the tuor suppressor activity of E2A; lck- idl and Ick- id2 transgenic mice
develop T cell lymphoma (Kim et aI. , 1999; Morrow et aI. , 1999).
Cell Cycle and Leukemia
Uncontrolled proliferation is a hallmark of cancer, and the frequent mutation of
cell cycle regulatory machinery in human cancers underscores the importance of tight
control of cell cycle machinery. The eukaryotic cell cycle is regulated by cyclin-
dependent kinases (CDKs), which bind to their activator parers, cyclins D , E , and A.
Following quiescence (Go), mitogenic stimulus induces expression of D-tye cyclins
(cyclin Dl , D2 and D3). Since cyclin D is only synthesized following mitogenic
stimulation, and is negatively regulated by SKP/CUL-mediated ubiquitination(Yu et aI.
1998), constant mitogenic stimulation is required to proceed through the 
IS restrction
point. Cyclin D binds either CDK4 or CDK6, which then phosphorylates the
retinoblastoma protein (pRB). In an unphosphorylated form, pRB binds and negatively
regulates the transcription factor, E2F. However, upon phosphorylation, pRB releases
E2F , allowing E2F to induce expression of many S-phase genes: dihydrofolate reductase
(DHFR), thymidine kinase (TK), cdc2, E2Fl , cyclin A, and importantly cyclin E
(DeGregori et aI. , 1995; Duronio and O'Farell, 1995; Schulze et aI. , 1995). Cyclin E
binds CDK2 and catalyzes the GIIS transition through the continued phosphorylation of
pRB , and other substrates essential for replication origin firing, centrosome duplication
and hi stone- biosynthesis (Ma et aI. , 2000; Okuda et aI. , 2000; Zhao et aI. , 1998). Once
cells enter S-phase, phosphorylation of cyclin E by CDK2 results in its ubiquitin-
dependent proteolysis (Won and Reed, 1996).
~~~
Multiple proteins inbit cyclin D/CDK4 6 complexes, and therefore negatively
regulate GI progression. One family of cyclin-dependent kinase inhbitors (CDKI)
includes p21 CIPI , p27
KIPI
, and p57KIP2, which all contain an amino-terminal CDK
inhibitory domain (Chen et aI., 1995; Luo et aI. , 1995). These CDKIs induce Gl arrest
when ectopically expressed (el-Deiry et aI., 1994; Harer et aI. , 1993; Lee et aI., 1995;
Polyak et aI. , 1994), and bind to and inhbit cyclin AlCDK2 cyclin B/CDC2 cyc1in
E/CDK2 and cyclin D/CDK4 complexes in vitro (Lee et aI. , 1995; Xiong et aI., 1993).
Another family ofCDKIs is the inhibitors ofCD and CDK6 , which includes p16
INK4a
p15 INK5b , p18INK4C and p19INK4d These inhbitors specifically bind and inhibit cyclin
DlICDK4 and CDK6 , but do not inhbit the other CDKs (Guan et aI. , 1994; Hanon and
Beach, 1994; Hirai et aI. , 1995; Serrano et aI., 1993). In addition, ectopic expressionof
the IN4a family members induce G 1 arest in multiple cells (Greenwald and Rubin
1992; Hirai et aI. , 1995).
Cell cycle and cancer
Mutations targeting the cell cycle regulatory proteins are common in human
cancers. For example, chromosomal translocations affecting cyclin Dl are observed 
parathyroid adenomas containing inv(Il)(p15;qI3) (Motokura et aI. , 1991), and in B
lineage mantle cell lymphomas with t(II;14)(q13;q32) (Willams et aI., 1993).
Amplification of cyclin Dl (llq13) is commonly observed in adult carcinomas (Somers
et aI. , 1990; Yoshida et aI. , 1988), and amplification of the catalytic partner of cyclin Dl
CDK4, is amplified in sarcomas and gliomas (Khatib et aI., 1993; Reifenberger et aI.
1994; Schmidt et aI. , 1994; Su et aI. , 1997). In addition, mutation of the INK4a allele is
commonly observed in melanoma, gliomas, ALL , and sarcomas , and mutation of RB 
associated with retinoblastomas and osteosarcomas (Borg et aI., 1996; Francke and Kung,
1976; Friend et aI., 1986; Godbout et aI. , 1983; Hatta et aI. , 1995; He et aI. , 1994; Kovar
et aI., 1997). However, other cell cycle regulatory molecules , for example, cyclin A
cyclin E, and p2l CIPI are rarely found mutated in human cancers, suggesting that
regulation of the GI IS restrction point is critical to prevent tuorigenesis.
E2A and cell cycle
There is substatial evidence implicating E2a in cell cycle control. Ectopic
expression ofE47 in NIH3T3 cells induces growth inhbition, as indicated by a reduction
in colony forming effciency (CFE) (Peverali et aI., 1994). In addition, the other E
proteins , Heb and E2- , also confer similar growth inhibition in colony forming assays
(pagliuca et aI., 2000). Moreover, when endogenous levels of E47 were restored in
Jurkat cells by inhibiting Tall/E47 heterodimers, the cells underwent growth arest and
subsequent apoptosis (Park et aI., 1999). This growth inhbition is consistent with the
hypothesis that E proteins transcriptionally regulate CDKIs. In fact, E boxes are present
in the proximal promoter sequences of p2l ClP, pI5 INK5B , and p16INK4 (Pagliuca et aI.
2000; Prabhu et aI., 1997). In addition, E47 induces transcription of these CDKIs in
reporter assays (Pagliuca et aI., 2000), which can be inhibited by Id or Tall expression
(Hansson et aI. , 2003). Moreover, expression ofIdl , Id2, and Id3 stimulates cell growth
in various cell types (Atherton et aI., 1996; Deed et aI. , 1997; Iavarone et aI., 1994;
Lasorella et aI. , 1996; Prabhu et aI. , 1997). Antisense oligonucleotides against Id proteins
prevent G progression, suggesting E2A induces cell cycle arrest in vitro (Barone et aI.
1994; Hara et aI., 1994). Moreover E47 null mice show a 3-fold increase in BrdU
positive DN3 cells, suggesting that E47 also contributes to a cell cycle arest in vivo
(Engel and Mure , 2004).
However, additional evidence indicates E2A expression may not inhbit the cell
cycle but may promote cell cycle progression (Engel et aI. , 2001; Pagliuca et aI. , 2000;
Song et aI. , 2004; Zhao et aI. , 2001). Closer analysis following ectopic E47 expression
demonstrates that the reduced CFE may be explained by increased levels of cell death
instead of growth arrest (Engel and Mure, 1999; Pagliuca et aI. , 2000; Zhao et aI. , 2001).
In addition, a conditional E47 system demonstrated E47 expression promotes
proliferation in B and non-B cells (Zhao et aI. , 2001), whereas E47 suppression caused a
downegulation of cyclin D3 , cdc2 , p27 and p21 expression (Chu and Kohtz, 2001; Zhao
et aI. , 2001). Consistent with this , E47 trans activated the cyclin D3 promoter in reporter
assays (Song et aI. , 2004), and fetal liver cells from E2A null mice display reduced
levels of cyclin D2 and cyclin D3 (Zhao et aI., 2001).
INK4A
A deletion of chromosome 9p21 is commonly observed in leukemic patients
(Chilcote et aI. , 1985; Diaz et aI. , 1988; Hecht and Hecht, 1986; Pollak and Hagemeijer
1987) and the tumor suppressor, p16INK4a, was mapped to this chromosomal region.
p16INK4a was first identified through its interaction with CDK4 , and later established to be
an inhibito of cyclin D/CDK4 complexes in vivo (Serrano et aI. , 1993; Xiong et aI.
1993). Binding of p16INK4a to CDK4 or CKD6 inhibits the interaction between CDK4
and cyc1in D, and thereby prevents the catalytic activity of the cyclin D/CDK4-
complexes (Serrano et aI. , 1993). Expression of p l6INK4a inhbits the phosphorylation of
RB in vitro and in vivo (Koh et aI., 1995). Importantly, ectopic expression of p16
INK4a
induces a G) arest, which is dependent on the presence of fuctional RB (Koh et aI.
1995; Lukas et aI., 1995; Medema et aI., 1995). Significantly, single amino-acid
mutations in p 16INK4a observed in human cancer patients prevent its ability to bind
cyclinD/CDK4, phosphorylate RB , and induce G 1 arrest (Koh et aI. , 1995; Lukas et aI.
1995).
Interestingly, within the p16INK4a allele, another tuor suppressor was discovered
to be encoded by an !lternative reading frame (Quelle et aI. , 1995). The p l6INK4a
transcript is encoded from exon la, 2 and 3 , whereas p14ARF (p19Arf in mice) is encoded
byexon Ip, 2 and 3. Although both genes utilize exons 2 and 3 , they are controlled by
distinct promoters and are transcribed in alternate reading frames. Therefore , p16
INK4a
and p14ARF are divergent in both sequence and fuction. Ectopic p19
ARF expression in
NIH3T3 cells, which lack the p16INK4a allele , induced a arest indicating that
p 19ARF fuctions independently of p l6
INK4a (Quelle et aI., 1995). In addition, p 19ARF
does not interact with cyclins A, D, E, CDK2, CDK4, CDK6 , or CDC2 demonstrating
that p 19
ARF does not fuction as a CDKI to induce cell cycle arrest (Quelle et aI. , 1995).
p19ARF interacts in vivo with Mdm2, preventing the Mdm2-induced ubiquitination and
degradation of p53 (Pomerantz et aI. , 1998). Expression of p 19AR is upregulated upon
hyperproliferative signals from Ras, Myc, ElA, and E2F and through the inhibition of
Mdm2, results in either p53-dependent apoptosis or cell cycle arrest (Bates et aI., 1998;
de Stanchina et aI. , 1998; Palmero et aI. , 1998; Zindy et aI. , 1998). For this reason
P 19
AR has been proposed to fuction as a sensor of oncogenic stresses , resulting in the
apoptosis or cell cycle arest of cells displaying aberrant proliferation.
Mice deficient for both p l6Ink4a and p 19Ar were generated by the targeted
disruption of the shared exons 2 and 3 of the ink4a allele. Ink4a/arf-/- mouse embryonic
fibroblasts (MEFs) overcome senescence at a faster rate compared to wild tye MEFs
and are susceptible to transformation with activated ras (Ha-rasVaIl2) (Serrano et aI.
1996). Consistent with the ink4a/arf allele encoding two tuor suppressors, 69% of
ink4a/arf-/- mice develop spontaeous fibrosarcomas and lymphomas with a mean
latency of 203 days (Serrano et aI. , 1996). Ink4a exon 1 was then disrupted to create
plgarf knock-out mice, of which 80% develop various malignant tuors, including
sarcomas and T -cell lymphoma within the first year (Kamijo et aI. , 1999; Kamijo et aI.
1997). Additionally, pl~rf
/- 
MEFs also demonstrate increased proliferation and
susceptibility to H-ras-mediated transformation (Kamijo et aI. , 1997). Next p16ink4a
mice were generated through the tageted disruption of exon 1 a. p 1 nk4a /- MEF s do not
exhibit increased immortalization, or susceptibilty to H-ras-mediated transformation as
observed in ink4a/arf-/- andpl~rf
/- 
MEFs (Serrano et aI. , 1996; Sharpless et aI. , 2001).
However, the absence of p16lnk4a stil results in tuor formation; 25% of p16ink4a
/- 
mice
develop soft-tissue sarcomas , splenic lymphomas and melanomas with a mean latency of
disease of 300 days (Sharpless et aI. , 2001).
Ink4a and Leukemia
A deletion of chromosome 9p21 , which encodes the tumor suppressors , p 16 INK4a
pI9ARF , and p15INK5b is commonly observed in leukemic patients (Chilcoteet aI. , 1985;
Murhy et aI. , 1989). It has been assumed that the loss of p l6INK4a primarily contrbutes
to leukemogenesis. In fact, a summar of numerous published studies demonstrated that
1 -
326/564 (58%) of T-ALL patients display deletions of p16INK4a (Drexler, 1998).
Disruption of the INK4a locus occurs though deletion via ilegitimate V(D)J
recombination (Cayuela et aI. , 1997), inactivating point mutations (Ohnshi et aI., 1995;
Quelle et aI. , 1997), or methylation of CpG islands in the promoter region (Guo et aI.
2000). In addition, tuor associated mutations in exon 2 inhbit the activity of p l6INK4a
to induce growth arest, whereas the same mutations do not affect the fuctional activity
ofp14ARF (Quelle et aI. , 1997).
Additional studies suggest deletion of p14ARF may also contribute to
leukemogenesis. For example , the majority of published studies mentioned above detect
loss of P 16 INK4a by a loss of exon 2 , which also indicates deletion of p 14 AR. Therefore
the majority of T-ALL patients also exhbit deletions of p14AR (Haidar et aI., 1995;
Kamb et aI., 1994; Okuda et aI., 1995). In addition, some leukemic patients display
deletions of p14 , whereas p16INK4a remains intact (Gardie et aI., 1998). Therefore
clinical studies implicate the deletion of p16INK4a and/or p14ARF in leukemia, but fail to
distinguish the relative roles of each (Figue 2). Consistent with this possibility,
ink4a/arf, p16ink4a and pl~rf deficient mice all develop lymphoid malignancies
(Kamijo et aI. , 1997; Serrano et aI., 1996; Sharpless et aI. , 2001).
Importantly, a recent clinical study finds 78% of TALI-expressing leukemic
patients contain deletions of exon 2 of the INK4a allele, suggesting that loss of both
p16INK4a and p14AR may contribute to leukemogenesis (Ferrando et aI. , 2002). This
suggests that loss of the INK4a allele may cooperate with TALI expression in
leukemogenesis. The work presented in ths thesis demonstrates that loss of the ink4a
allele cooperates with Tall expression to induce leukemia in the mouse. Moreover, in
contrast to the general perception that loss of p 16Ink4a is the important genetic event in
leukemogenesis, we provide genetic evidence that Tall expression cooperates with not
only the loss of p 16
Ink4a 
but also p 19
The Notch family
The four members of the mammalian Notch family (Notchl-4), are
evolutionarily-conserved single-pass transmembrane receptors essential for cell fate
decisions (Artavanis- Tsakonas et aI., 1999). Notch 1 is a 300kDa polypeptide that
undergoes proteolytic cleavage by a fun-like protease in the Golgi apparatus to yield
two associated subunits, a transmembrane subunit (NTM) and an extracellular subunit
(NC) (Logeat et aI. , 1998). The NTM subunit contains a RAM domain and an ankyin
repeat (ANK) domain, which are both important for protein-protein interactions
(Kurooka et aI. , 1998). The NTM also contains the negative regulatory PEST domain
and a transactivation domain (Rechsteiner, 1988). The NEC domain consists of 36
epidermal growth factor (EGF)-like repeats responsible for ligand binding, as well as
three lin-12 repeats (LNR) (Rebay et aI. , 1991).
Activation of the Notch receptor occurs by binding to ligands of either the
Jagged- or Delta-like families (Bettenhausen et aI., 1995; Lindsell et aI., 1995).
Following ligand-binding, Notch undergoes two successive cleavage events. The first
cleavage occurs just external to the transmembrane (TM) region by a TNF -(L converting
enzyme (TACE), a member of the ADAM metalloproteases (Brou et aI. , 2000). The
second cleavage occurs withn the TM region at valine 1744 by a y-secretase complex
that includes Presenilinl , Aphl , Nicastrn, and Pen-2 (De Strooper, 2003; De Strooper et
aI., 1999). These cleavages allow the intracellular region of Notchl (Notch ) to
translocate to the nucleus, where it induces transcription as par of a multifactorial
complex, including CSL/RP- , Mastermind, and p300lCBP (Oswald et aI. , 2001; Wu
et aI. , 2002). CSL/RP-JK (also known as CBF1 , SuCH), Lag- I), normally represses
transcription through the interaction with corepressors N-CoR/SMRT, KyoT2 , and CIR
(Hsieh et aI., 1999; Kao et aI. , 1998; Taniguchi et aI., 1998). However, through the
interaction of CSL/RP-JK with Notch , the corepressors are displaced, and Notch
recruits the co activators p300 , PCAF , and GCN5 (Kurooka and Honjo, 2000; Oswald et
aI., 2001). Notch signaling is negatively regulated through ubiquitin/proteasome
degradation pathway; Sel- lO (Wu et aI. , 2001), or the HECT-domain protein Itch (Qiu et
aI., 2000) fuction as E3 ubiquitin ligases of Notch in vitro. Additionally, Numb
negatively regulates Notch activity by faciltating interaction with the E3 ligase Itch
(McGil and McGlade, 2003). The Fringe family (Lunatic , Manic, and Radical) are
glycosyltransferases and modify Notchl fuction by modulating their response to ligand
(Moloney et aI. , 2000; Yang et aI. , 2005). The numerous proteins regulating the Notch
pathway indicate the importance of tightly controlled Notch signaling.
Notch function
The Notch protein family regulates the differentiation of progenitor cells and
controls cell fate specification during development (Artavanis- Tsakonas et aI., 1999;
Greenwald, 1998). The Notch gene was originally identified in Drosophila melanogaster
as a loss of fuction mutation, resulting in a notch phenotye withn the wing margin
(Morgan, 1917). Notch uses lateral inhbition to control cell fate specification during
development of numerous tissues (Simpson, 1990). For example , in developing nervous
system of Drosophila a few cells within a population of equipotent cells are selected for
Notch activation. Following Notch activation, Suppressor of Hairless (Su(H))
transcriptionally activates Enhancer of split (E(Spl)), which through the inhibition of
acaete-scute complex, downegulates the expression of Delta and other proneural genes
(Bailey and Posakony, 1995; Kunisch et aI., 1994). Therefore, cells receiving a Notch
signal develop into an epidermal fate , whereas neighboring cells develop into neural
precursors. Consistent with the role of Notch in regulating differentiation of progenitors
uncontrolled Notch signaling often inhbits differentiation along a specific fate pathway.
For example , ectopic expression of Notch 1 has been shown to inhibit the differentiation
of myeloid (Bigas et aI. , 1998), granulocytic (Milner et aI. , 1996), lymphoid (Wilson et
aI. , 2001), and intestinal cells (Fre et aI. , 2005; van Es et aI. , 2005).
Targeted disruption of the notchl allele in mice results in embryonic lethality at
E(11.5) due to abnormal somitogenesis (Conlon et aI., 1995; Swiatek et aI., 1994).
Notchl-deficient embryos developed normally until E(9.5) (14 somite stage), and then
displayed growth arrest, neural-specific cell death, and pericardial edema (Conlon et aI.
1995; Swiatek et aI., 1994). This phenotype is consistent with Notch fuctioning as 
component of the segmentation clock during development (Bessho and Kageyama, 2003;
Rida et aI. , 2004). In addition, Notch has been reported to be essential in various stages
of neural tissue development (Y oon and Gaiano , 2005), and pancreatic cell differentiation
(Apelqvist et aI. , 1999). The importance of the Notch signaling pathway during multiple
stages of development is underscored by the embryonic or postnatal lethality phenotype
observed in mice deficient in CSL/RP-JK (Oka et aI. , 1995), Presenilinl (Shen et aI.
1997), Notch2 (Hamada et aI., 1999), or processing-deficient Notchl knock-in mice
(Huppert et aI. , 2000).
Notch family members are implicated in development and maintenance of
hematopoetic stem cells (HSC). Notchl and Notch2 are expressed in hematopoietic
progenitor cells (Bigas et aI. , 1998; Milner et aI. , 1994), and notchl-deficient paraaortic
splanchnopleura (P-Sp) organ cultues demonstrate impaired hematopoetic cell
development (Kumano et aI. , 2003). Additionally, expression of activated Notchl 
murine primitive bone marow cells resulted in the development of cytokine-dependent
hematopoietic stem cell line with the capacity to differentiate into cells with either
myeloid and lymphoid characteristics in vivo and in vitro (Varum-Finney et aI. , 2000).
Moreover expression of Notch 1 inhibits myeloid, eryhroid, and granulocytic
differentiation in vitro, and allows expansion of undifferentiated cells (Bigas et aI. , 1998;
Kumano et aI. , 2001; Milner et aI. , 1996). Similarly, treatment with Notchl ligands
Jaggedl , Jagged2 , and Deltal inhibit differentiation ofhematopoetic stem cells (Carlesso
et aI. , 1999; Han et aI. , 2000; Varnum-Finney et aI. , 1998).
Furher analysis of the notch-deficient mice indicated a role for Notch signaling in
regulating embryonic vascular morphogenesis (Krebs et aI., 2000). Both Notchl-
/- 
and
NotchllNotch4 double knock-out (DKO) mice display severe defects in angiogenic
vascular remodeling in the yolk sac, placenta and embryo (Kebs et aI. , 2000). In
addition jaggedl and deltal-deficient mice die from vascular defects and hemorrhaging
at E(10.5) (Hrabe de Angelis et aI. , 1997; Xue et aI., 1999). In addition, the importance
of Notch signaling in adult vascular homeostasis is indicated by the presence of missense
mutations in Notch3 in patients with CADASIL, a degenerative vascular disease (Joutel
et aI. , 1996).
Notch and Hematopoesis
Notchl is known to play an essential role in T cell fate specification. Notch
receptors and their ligands are expressed widely in bone marrow and thymic stromal cells
durng T cell differentiation (Anderson et aI. , 2001; Radtke et aI. , 2004; Singh et aI.
2000). Several lines of evidence suggest that in lymphoid progenitor cells, the default
pathway is B cell development, but upon increased Notch activation, progenitors
differentiate into T lymphocytes. Conditional disruption of notchl in the thymus using
the Mx l-Cre system resulted in thymocyte differentiation arest and the ectopic presence
of B cells in the thymus (Radtke et aI., 1999; Wilson et aI., 2001). Moreover,
pharacologic inhbition of Notch signaling with y-secretase inhbition in fetal thymic
organ cultues (FTOC) also blocked thymocyte differentiation and resulted in the
development of B lymphocytes (Doerfler et aI., 2001; Hadland et aI., 2001).
Furhermore, ectopic expression of the Notch modulator, Lunatic Fringe, in the thymus
resulted in a similar decrease in T cells and increase of B cells (Koch et aI. , 2001).
Conversely, ectopic expression of Notch 1 IC in the bone marrow results in early block in B
cell maturation and the inappropriate development of T cells in the bone marrow
comparment (Pui et aI. , 1999).
Notchl is implicated in various fate decisions during thymocyte development;
such as, the ap versus yo lineage decision (Ma et aI. , 1999), and the CD4 versus CD8
lineage decision (Deftos et aI. , 2000; Robey et aI., 1996). Although conditional
disruption of Notchl induces a thymocyte differentiation arrest and a accumulation of
thymic B cells, the development of myeloid, NK, and dendritic cells was normal
suggesting that Notchl is dispensable for normal development of myeloid and other
lineages (Radtke et aI. , 1999).
Notch and E2A
Vertebrate Notchl is capable of inhibiting MyoD fuction, a myogenic class II
bHLH protein (Kopan et aI. , 1994; Shawber et aI. , 1996). Similarly, Notchl signaling
also has been reported to inhibit the class I bHLH protein, E2A. The intracellular
domains of Notchl , Notch2, and the Notch target gene, Deltex, completely repress the
transcriptional activity of E2A in transfection studies (Ordentlich et aI., 1998).
Mutational analysis demonstrated that transcriptional inhbition of E2A is independent of
Notch binding to CSL/RP- , suggesting that inhibition is independent of CSL/RP-
, -mediated transcription (Ordentlich et aI. , 1998). The authors speculate Notchleltex
inhbits Ras signaling, thereby preventing Ras-mediated activation of E47 (Ordentlich et
aI. , 1998). Closer analysis demonstrated that Notch may inhbit E2A activity through its
abilty to promote the ubiquitination and degradation of E2A in a CSL/RP-JK-
dependent manner (Nie et aI. , 2003). Specifically, in the presence of Notchl signaling,
E2A is phosphorylated by MAP kinases, ubiquitinated by SCFskp2 and degraded by the
proteosome (Nie et aI. , 2003). A preubiquitination complex (PUC) consisting of E47
CHIP , Hsc70, and Skp2 forms to facilitate the interaction of E2A with the E3 ligase
SCFskp2 (Huang et aI. , 2004). Consistent with this pathway, Notchl has recently been
shown to directly induce SKP2 expression (Sarento et aI. , 2005).
Another report demonstrates Notch signaling may inhibit the abilty of E2A to
bind DNA (Talora et aI. , 2003). Notchi transgenic mice have drastically reduced levels
of E box-binding complexes, which correlates with a 9-fold increase in Idl levels
suggesting Notch inhbits E2A by inducing transcription of Id 1 (Tal ora et aI., 2003).
Following TCR-mediated ligation, the ERKAPK induces Id3 expression levels and
inhibits E2A activity (Bain et aI. , 2001). Similarly, Notch3 downegulated E2A activity
by the induction of Id 1 , which is dependent on pre- TCR signaling through the
ERKAPK pathway (Talora et aI. , 2003).
Notch and leukemia
The human NOTCHl gene was originally identified from the t(7;9)(q34;q34.
translocation, which juxtaposes the NOTCHI gene to the TCR locus (Ellis en et aI.
1991). This translocation is associated with less than 1 % of T cell leukemic patients , and
results in a trcated allele that signals independently of ligand binding. This
constitutively-active protein induces transformation in vitro and induces T -cell leukemia
in mouse bone marrow reconstitution experiments (Capobianco et aI. , 1997; Pear et aI.
1996). In addition, transgenic mice misexpressing the activated allele of Notchl in the
thymus develop aggressive, immatue T ,cell tuors (Beverly and Capobianco , 2003;
Deftos and Bevan, 2000; Robey et aI., 1996). Mutational analysis demonstrate that the
ANK repeats and the transactivation domains are required for in vitro transformation
whereas the RA and PEST domains are dispensable (Aster et aI., 2000). In addition
,-it
activation of the Notchl pathway cooperates with other oncogenes to induce T-cell
malignancies. Activating mutations in Notchl are observed in retroviral insertional
mutagenesis (R) of e2a-pbxl transgenic mice and MMTvD/myc transgenic mice
(Feldman et aI. , 2000; Girard et aI. , 1996). Other members ofthe Notch family are also
implicated in leukemogenesis. For example, trcation of NOTCH2 is capable of
transformation in vitro (Capobianco et aI. , 1997), and notchi transgenic mice develop
T -cell leukemia (Bellavia et aI. , 2000). Lastly, trucations of Notch4 are observed in a
mouse mammary tumor virus (MTV) insertional mutagenesis screen (Robbins et aI.
1992).
Recent evidence suggests that NOTCHI activation may contribute to a greater
frequency ofT-ALL patients than the.(l % displaying the t(7;9)(q34;q34.3) translocation.
Screening various cell lines found NOTCH 1 and the NOTCH target gene, HESl
overexpressed in the majority of T cell leukemia patients (Bellavia et aI., 2002;
Chiaramonte et aI., 2003; Jundt et aI., 2002). In addition, mutations within the
heterodimerization domain (HD) andlor the PEST domain of Notch 1 are seen in 56% of
ALL patients (Weng et aI. , 2004). Mutations of the HD domain have been suggested
to weaken the association between the NTM and NEC subunits, increasing the
probability of ligand-independent activation. PEST mutations often result in frame shift
mutations and a premature STOP , thereby deleting the negative regulatory PEST domain
and increasing the stability of NTM domain. Significantly, 39% of TALI-expressing
leukemic patients display NOTCH 1 mutations , suggesting NOTCHI mutations may
cooperate with TALI during leukemogenesis (Weng et aI. , 2004).
The work presented in this thesis demonstrates that using RI we identified
Notchl as a common insertion site, suggesting Notchl activation may cooperate with
Tall expression during leukemogenesis. Interestingly, the vast majority of spontaneous
tall tumors express cleaved Notchl protein and Notch target genes, Deltex and Hesl
indicating that the tuors remain dependent on Notch signaling. Moreover, we find
frequent mutations in the PEST and/or HD region of notchl as well as sensitivity to
treatment with y-secretase inhbitors. In an attempt to determine how Notchl activation
contributes to leukemia, I generated a conditional Notchl cell line. This cell line
demonstrates continuous Notchl expression is essential for leukemic cells, as cells
undergo G 1 arrest and apoptosis in the absence of Notch 1 signaling.
C. Elegans E2A-HLF Leukemia
ces- E2A-HLF
ces- Slug
egl- BH3 only
ced- Bel-
ced- Caspase
ced-4 Cascade
Death of 2 NSM Survival of pro-B lymphocytes
Figure 1: Model of conserved survival pathway in C. Elegans and putative
leukemogenic function of E2A-HLF. CES-2 induces the death of 2 neurosecretory motor
neurons durng C. elegans development by inhbiting the anti-apoptotic protein CES-l. CES 1
inhibits apoptosis by binding and inhibiting the pro-apoptotic protein, EGL- , which therefore
inhbits thecaspase cascade. It has been proposed that E2A-HLF replaces a B cell specific
CES-2 homolog and induces the transcription of SLUG. SLUG inhbits apoptosis by
sequestering pro-apoptoic BH3 proteins, thereby allowing BCL- to inhibit the caspase
cascade.
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Figure 2. Schematic representation of the IN4a locus and genetic mutations associated
with cancer. A. The p15IN4b , p16IN4a, and p14AR genes are shown schematically. Black
arrowheads represent point mutations associated with human cancers, and red arrowheads
represent methylation of CpG promoter regions. B) Deletions associated with T-ALL
represented below the schematic representation of the INK4a allele. The deletions are
organized by the alleles deleted.
CHAPTER 
E2A-HLF EXPRESSION REQUIRES ADDITIONAL
COOPERATING MUTATIONS TO INDUCE
LEUKEMIA IN THE MOUSE
Introduction
E2A-HLF is a chimeric transcription factor resulting from the t(17;19)(q2l-
22;p13) translocation, which is associated with 1% of B-ALL (Raimondi et aI., 1991).
Although the occurence of the t(17;19)(q2l-22;p13) translocation is rare , the prognosis
is exceedingly poor; all the documented patients displaying E2A-
HLF died as a result of
their leukemia (Devaraj et aI. , 1994; Hunger et aI. , 1994; Ohyashiki et aI. , 1991).
There are two distinct types of translocations that result in the E2A-HLF fusion
protein, depending on the breakpoint withn E2A (reviewed in (Hunger, 1996)). In type I
translocations , the breakpoint occurs within intron 12 ofE2A and fuses the first 12 exons
of E2A to exon 4 of HLF (Hunger et aI. , 1994; Hunger et aI. , 1992; Inaba et aI. , 1992). A
direct fusion would not conserve the reading frame of HLF exon 4. However
, an
uncommon event occurs in which intronic DNA and nontemplated nucleotides are
inserted, which conserves the reading frame of HLF (Hunger et aI., 1994). In type II
translocations, the breakpoint occurs within intron 13 of E2A and results in a direct
fusion of the first 13 exons of E2A to the fourh exon of HLF (Hunger et aI., 1994).
Therefore , both types of translocation conserve the reading frame of HLF and result in a
fusion protein containing two strong transactivation domains from the bHLH protein
E2A , fused to the basic leucine zipper (bZIP) ofHLF (Hunger et aI., 1994).
The oncogenicity of the E2A-HLF fusion protein have been demonstrated through
the transformation of both NIH3T3 cells in soft-agar assays (Y oshihara et aI. , 1995), and
bone marrow precursors in cooperation with BCL-2 expression (Smith et aI., 2002).
Mutational analysis demonstrated that transformation depends on both the transactivation
domains of E2A and the DNA-binding and protein dimerization domains of HLF
suggesting that both E2A and HLF contrbutes to the leukemogenicity of the fusion
protein (Y oshihara et aI. , 1995).
The role of HLF in an evolutionarily conserved surival pathway has been
proposed due to the significant homology between the bZIP domain of HLF to the bZIP
domain of the C. elegans apoptotic protein, CES- CES-2 induces death in two
neurosecretory motor neurons (NSM) durng embryogenesis (Ells and Horvitz, 1991).
Genetic studies indicated that CES-2 is a negative regulator of the anti-apoptotic protein
CES- l (Ells and Horvitz, 1991). Importantly, representative differential analysis (RDA)
demonstrated that E2A-HLF induces the expression of SLUG, a homolog of the 
elegans apoptotic protein CES-l (Inukai et aI., 1999). Consistent with E2A-HLF
interfering with a surival pathway, expression ofE2A-HLF inhbits apoptosis in varous
cytokine-dependent cell lines following cytokine withdrawal (Inaba et aI. , 1996; Inukai et
aI., 1998). In addition, E2A-HLF abrogates p53-induced apoptosis (Altua et aI. , 1998),
whereas fuctional inhibition ofE2A-HLF in t(I7;19) cell lines induces apoptosis (Inaba
et aI. , 1996). Therefore, E2A-HLF may induce leukemia by inappropriately inducing the
anti-apoptotic protein, SLUG, and thereby interferes with an evolutionarily conserved
surival pathway, resulting in the enhanced surival ofpro-B lymphocytes (Figure 1).
Two groups generated transgenic mouse models overexpressing E2a-Hlf under
control of lymphoid-specific promoters (Honda et aI. , 1999; Smith et aI., 1999). In
contrast to the B-ALL observed in t(I7;19) patients , both e2a-hlf transgenic models
developed T-cell malignancies and rarely B-cell malignancies. The development of T-
ALL in these transgenic mice precluded their use in determining how E2a-Hlf contributes
to trsformation of B cell prgenitors and leukemogenesis. One trangenic model
demonstated rednced ilymocyte numhers due to increased ilymocyte apoptosis , and a B
cell matuation arrest (Honda et aI. , 1999). The other transgenic model displayed a
progressive T cell differentiation arest, thymic involution, and the development of an
unusual CDT4 8- thymocyte population (Smith et aI. , 1999). Expression levels of E2a-
Hlf in the lymphoid lineages varied considerably between the two models which may
partially explain the phenotyic differences. In addition, the differences in phenotype
may also be explained by trans gene insertional effects, or trans gene copy number.
To more accurately mimic the t(17;19) human translocation associated with B-
ALL , and to determine how E2A-HLF induces B cell transformation, we generated e2a-
hlfknock-in mice. Similar to leukemic patients , these mice expressed the E2a-Hlffusion
protein under control of the endogenous e2a promoter. As a result, one e2a allele is the
inactivated by the mutant allele , further mimicking the human translocation. I obtained
germline transmission of the mutant e2a-hlf allele, and the e2a allele was disrupted
through this mutation. Homozygous e2a-hlf knock-in mice display a T cell
differentiation arrest and a complete lack of B lymphocytes, similar to e2a null mice
(Bain et aI. , 1994; Zhuang et aI. , 1994). However E2a-hlfknock- in mice fail to develop
leukemia, even following chemical mutagenesis, indicating that E2a-Hlf expression
requires additional cooperating mutations to induce leukemia in the mouse.
Results
Generation of E2a-Hlf Knock-In Mice
To recapitulate the t(17;19)(q2l-22;pI3) translocation observed in B-ALL
patients, we generated an e2a-hlfknock- in mouse using homologous recombination. We
modeled the type I translocation, which fuses the first 13 exons of E2A to exon 4 of HLF
and includes the insertion of 53 nucleotides to conserve the reading frame of HLF
(Hunger et aI., 1994; Hunger et aI. , 1992; Inaba et aI., 1992). The fusion region
containing a mouse genomic fragment encoding 
e2a exons 10-13, the 53 bp DNA linker
and human HLF exon 4 was generated by overlap PCR. rabbit globin
polyadenylation cassette was inserted downstream of the translational stop codon of 
HLF
exon 4 to ensure proper stability of the fusion gene transcript. 
The targeting construct
also contained a neomycin (NO) drg resistance marker and a herpes-simplex virus
thymidine kinase (TK) gene to facilitate positive and negative selection, respectively
(Figure 3). The e2a-hlf knock-in targeting constrct was electroporated into AB2.2
embryonic stem (ES) cells, and underwent positive (G418) and negative (FIAU)
selection. Four hundred ES cell clones were screened for homologous recombination
using Southern blot analysis; ES cell clones were digested with 
EcoRI and a 3' flanking
probe was used to identify the four clones that correctly displayed both the wild type
l8.8kb and the mutant 6.9kb bands (Figure 4). Further analysis with a 5' flanking probe
demonstrated that 3 of the 4 ES cell clones correctly underwent homologous
recombination (Figure 4).
Western blot analysis indicated ES cells express sufficient levels of E2a to allow
us to confirm proper expression of the e2a-hlftranscript in the targeted ES cells prior to
blastocyst injection (data not shown). RNA was extracted from wild-tye and tageted
AB2.2 cells , and e2a-hlf expression was assayed using RT-PCR. The targeted ES cells
expressed e2a-hlf whereas the wild tye ES cells did not, indicating that the e2a-hlfES
cells correctly expressed the fusion gene (Figue 5). Two targeted ES cell clones were
injected into blastocysts , and following transfer into foster mothers generated two high-
degree chimeras (50 and 80%). Mating the 80% chimera to C57BL/6 females gave rise
to agouti Fl progeny, and Southern blot analysis demonstrated germline transmission of
the e2a-hlfmutant allele (data not shown).
Phenotype of E2a-Hlf+ mice
E2a-hlf heterozygous mice were viable, fertile, and appeared phenotypically
normal. To analyze e2a-hlf expression, RNA was extracted from lymphoid tissues of
wild type and e2a-hlf+ mice. RT-PCR analysis using a primer to exon 12 of e2a and
exon 4 of hlf demonstrated presence of the e2a-hlf transcript in the bone marow, spleen
and the thymus of e2a-hlf+ mice but not in hematopoetic tissues of wild tye littermates
(Figure 6). Subsequent sequence analysis of the PCR product revealed correct splicing
from e2a exon 12, to exon 13 , to the 53bp linker, and finally to HLF exon 4.
Genotyping one hundred pups from heterozygous matings, 35 were wild type , 55
were e2a-hlf+ and 10 were e2a-hlfe2a-hlf which varied from the expected Mendelian
ratios (25 wild tye , 50 e2a-hlf+ and 25 e2a/hlfe2a/hlj. E2a/hlfhomozygous mice are
indistinguishable from littermates at birth, but within the first week displayed severe
growth defects , and all died within three weeks. Necropsy revealed that internal organs
appeared grossly normal , but muscle mass appeared reduced. The growth defects and
postnatal lethality is comparable to that observed in e2a null mice , consistent with the
fuctional disruption of E2a by replacing the bHLH domain exons of E2a with HLF in
the e2a-hlfhomozygous mice (Bainet aI. , 1994; Zhuang et aI. , 1994).
To determine if E2a-Hlf expression induced a differention arrest in lymphoid
tissues , we performed flow cytometry analysis on spleen, thymus , and bone marrow from
wild tye e2a-hlf+ and e2a-hlfe2a-hlf mice. Lymphocytes isolated from e2a-hif+
mice display no reproducible alterations in B or T cell profiles compared to wild type
lymphocytes (Figure 7). However e2a-hlf homozygous mice demonstrate a
differentiation arrest in both B and T lymphocytes. E2a-hlf homozygous mice contain
drastically reduced numbers of B220+ cells, similar to what is published for e2a null
mice (Bain et aI., 1994; Zhuang et aI., 1994) (Figue 7). However, the T cell
differentiation arrest observed in 
e2a-hlfhomozygous mice differs from that observed in
e2a null mice. E2a null mice demonstrate decreases in DP populations and subsequent
increases in DN and SP populations (Bain et aI. , 1997). However, e2a-hlfhomozygous
mice display an increase in DN and a decrease in DP cells , but do not display an increase
in SP cells (Figure 7). This demonstrates e2a-hlfhomozygous mice display a similar B
cell arrest but a divergent T cell arrest when compared to 
e2a null mice. This difference
in the T-cell differentiation arrest indicates that the e2a-hlf fusion gene not only
fuctionally disrupts the e2a allele, but provides additional biologic effects on T cell
differentiation.
E2a-Hlf expression requires cooperating mutations to induce leukemia in the mouse
Since E2A-HLF expression is associated with human B-ALL and e2a-hlf
transgenic mice develop T cell malignancies, we wanted to determine if mice expressing
E2a-Hlf under control of the endogenous e2a promoter develop leukemia. To test this
possibility, a small cohort of e2a-hlf+ mice (n=12) were aged and analyzed regularly for
signs of disease. No disease was observed in the cohort of e2a-hlf heterozygous mice
during the two years of the study, indicating that E2a-Hlf expression under control of the
e2a promoter is not suffcient to induce leukemia in the mouse.
It is possible that E2a-Hlf contrbutes to leukemogenesis , but requires additional
mutations. It has been previously shown that E2a-Hlf cooperates with Bcl-2 to transform
bone marrow progenitors in vitro (Smith et aI., 2002). To test the possibilty that E2a-Hlf
cooperates with Bcl-2 to induce leukemia, we mated the e2a-hlfknock- in mice to H2K- '
bcl- transgenic mice (Domen et aI. , 1998). Durng the course of study, no mice in the
small cohort of e2a/hlfbcl- mice developed disease (n=15), suggesting that E2a-Hlf
does not cooperate with Bcl-2 to induce leukemia in vivo.
To provide additional mutations to the e2a-hlfknock- in mice , we performed N-
ethyl-N-nitrosourea (END) mutagenesis. E2a-hlf+ mice (n=18) and wild type littermate
controls (n=9) were injected with 50mg/kg body weight with ENU, and monitored
regularly for 40 weeks for signs of disease. One ENU-treated e2a-hlf+ mouse (2705)
developed a CD4-negative , CD8-negative, and CD3-positive thymoma. In addition, ten
ENU-treated e2a-hlf and wild type mice were sacrificed after exhibiting weight loss
lethargy, and vaginal bleeding. Upon necropsy, these mice exhibited large uterine
masses (15mm), and histological analysis indicated endometrial hyperproliferation and
carcinoma. This phenotye has been previously published following ENU mutagenesis
in other mouse models (Mitsumori et aI. , 2000; Takahashi et aI. , 1996; Watanabe et aI.
2002). Overall , there was no difference in the surival in ENU-treated e2a-hlfknock-
mice compared to ENU treated wild type mice (Figue 8).
Discussion
We generated a knock-in mouse model to mImIC the t(17;19)(q2l-22;p13)
translocation observed inB-ALL p tients. The e2a-hlfheterozygous 
mice expressed e2a-
hlf fusion transcript in the lymphoid lineages , and appeared phenotypically normal. 
E2a-
hlfe2a-hlf mice displayed growth defects, postnatal lethality, and differention arrest in
both Band T cells. Ths phenotye is similar to phenotye of e2a-deficient mice, and
consistent with the replacement of the HLH domains of E2A with bZIP domain of HLF
(Bain et aI., 1994; Zhuang et aI. , 1994). However, the thymocyte differentiation arrest
observed in e2a-hlfhomozygous mice varied compared to e2anull mice, suggesting that
the e2a-hlf mutat allele is not a tre null allele, but that the bZIP domain of HLF
provides some biological fuction. Although the genetic backgrounds differ between the
e2a null mice and the e2a-hlf homozygous mice, it is unikely this accounts for the
phenotypic differences , since the e2a-hlfhomozygous mice were analyzed on two genetic
backgrounds , Balblc and 129/Sv.
There are multiple possibilities why expression of E2a-Hlf failed to induce
leukemia in this mouse model. The simplest explanation is that E2a-Hlf is not
suffciently expressed in the e2a-hlfknock- in mice. Although e2a-hlf RNA was detected
by RT-PCR, the absence of an informative antibody precluded our abilty to detect E2a-
Hlf protein expression levels. The Hlf antibody is no longer commercially available, and
the majority oftheE2A antibodies either react with the replaced bHLH domain, or reacts
with a non-specific band migrating at 62kDa, which is the size of E2a-Hlf. However, the
expression of e2a-hlf RNA and the minor phenotypic differences between the e2a-
hlfe2 hlf and e2a null mice suggests that the fusion protein is 
expressed. However
Northern blot analysis should be performed to establish the expression levels of the 
e2a-
hlftranscript, and compare them to cell lines from 
E2A-HLF leukemic patients.
Another explanation why the e2a-hlfmice did not develop leukemia 
may be that
the reciprocal fusion protein
, Hlf-E2a, may contribute to leukemogenesis, but is not
modeled in the e2a-hlfmice. A chromosomal translocation often results in two reciprocal
fusion proteins, and both may fuction durng leukemogenesis. For example
, in t(l7;19)
translocation, two fusion proteins, PML-RARa, and RARa-
PML, are expressed and
contribute to leukemogenesis (Alcalay et aI., 1992). In another example
, the reciprocal
fusion protein of BCR-ABL, ABL-BCR, is observed in 60% of 
leukemic patients
displaying the t(9;22) translocation (Melo et aI. , 1993). Although HLF-
E2A has not
been published to be expressed in t(17;19) leukemic patients , presumably because HLF is
not expressed in lymphoid cells , the recent evidence suggesting HLF is expressed in HSC
indicates HLF-E2A may contribute to leukemogenesis.
E2A-HLF has been shown to prevent apoptosis in various cell culture 
systems
(Inaba et aI. , 1996; Inukai et aI., 1998). However, its expression may actually induce
apoptosis in some instances. For example , thymus from 
e2a-hlf transgenic mice
displayed increased levels of apoptosis following 
TUNL staining (Honda et aI. , 1999).
Perhaps expression of E2a-Hlf is not compatible in lymphoid progenitors. 
Consistent
with this , both e2a-hlf transgenic models express low levels of E2a-
Hlf, despite using
transgenic constructs that previously yielded high expression levels in other transgenic
models (Adams et aI. , 1985; Yukawa et aI. , 1989). However, Annexin V staining of
';1;',.
spleen, thymus and bone marow from 4 week e2a-hlf /+ mice failed to reveal any
evidence of increased apoptosis (data notshown).
This experiment indicates that expression of E2a-Hlf under control of the e2a
promoter is not sufficient to induce leukemia in the mouse , suggesting multiple additional
mutations are necessary to cooperate with E2a-Hlf expression to induce leukemia in the
mouse.
t:j
Materials and Methods
Generation of e2a-hlfknock- in targeting construct
A 1.8kb genomic fragment of 5' homology was generated by combining a 800bp PCR
fragment containing 
e2a exon 10 with a lkb e2a fragment containing exons 11-13 (gift
from Yuan Zhuang). Using the 5' homology and the 
E2A-HLF cDNA (gift from Stephen
Hunger) as templates , overlap PCR was performed to insert the published 53bp of linker
DNA immediately downstream of 
e2a exon 13, and fuse it in frame to human 
HLF exon
4 (GenBank accession no. M95586). A B-globin polyadenylation cassette (pCAGGS)
was inserted immediately following 
HLF ex on 4. To enable positive selection, PGK-
neomycin cassette was inserted downstream of the B-globin polyadenylation signal. For
the 3' homology, a 3.2- kb EcoRV-HindIII e2a genomic fragment containing the bHLH
exons of e2a (gift from Gretchen Bain) was inserted following the PGK-Neo cassette.
Finally, a HSV-thymidine kinase cassette was inserted to facilitate negative selection.
Generation of e2a-hlfknock- in ES cells and chimeras
The e2a-hlf knock-in constrct was linearized at a unique Not! site, purified, and
electroporated into AB2.2 ES cells. Following positive and negative selection with G418
and FIAU, respectively, clones were picked and screened by Southern blot analysis. 
cell clones were digested overnight with EcoRI electrophoresed on a 1 % agarose gel
transferred to a nitrocellulose membrane and probed with 3' flanking probe. Putative
positives were additionally screened with a 5' flanking probe. Correctly targeted ES cells
clones were microinjected into C57BL/6 blastocysts and implanted into pseudopregnant
foster mice using standard protocols. Chimeric offspring are identified by presence of
agouti coat color and the highest degree chiera (80%) was mated to C57BL/6 females
to assay for germline transmission of the e2a-hlfmutat allele.
Mice
E2a-hlfhomozygous mice were maintained on 129Sv/Ev, and Balb/c backgrounds. To
genotype the e2a-hlf mice , PCR was performed to identify the presence of the e2a-hlf
fusion allele with JAS7 (5' CTC-CTT-CCT-CAA-GTC-AGC-CAC- ) and JAS15 (5'
GGT-GAC-ATT-TAG-GGA-CTC-CAG- ) and to identify the wild 
tye e2a allele with
JAS8 (5' CAA-GAT-GGA-GGA-CCG-CTT-GG- ) and JAS22 (5' CTA-AGT-CAC-
TCT-TCA-GCC-CTG-AG- ). To determine ifE2a-Hlf cooperated with Bcl-2 to induce
leukemia e2a-hlf mice were mated to H2K-bcl- mice (a gift from Jos Doman). Mice
were monitored regularly for signs of disease
Reverse- Transcriptase PCR
RNA was isolated from ES cells , bone marow, thymus and spleen using Trizol Reagent
(Invitrogen, Carls bad, CA). cDNA was synthesized using the Superscript First-Strand
Synthesis System (Invitrogen) and amplified with JAS13 (5' TCA-CAG-AGA-CCT-
CCC-GAC-TC- ) and JAS14 (5' GCA-AAA-ATG-CCA-TCC-TAC-AGG- ) to detect
presence of the fusion construct in the ES cells. To ensure correct splicing from exon 12
into the fusion construct, a 428 bp fragment corresponding to e2a ex on 12, exon 13
linker and HLF exon 4 was amplified with JAS8 (5' CAA-GAT-GGA-GGA-CCG-CTT-
) and JAS16 (5' GGT-TCT-CTT-TCA-GCC-TCC- 3). The resulting PCR product
was cloned into pCR4- TOPO (Invitrogen), and sequenced to confirm correct splicing.
Flow cytometry
Bone marow, spleen, and thymus were isolated from wild tye e2a-hlf+ and e2a-
hlfe2a-hlfmice and minced into single-cell suspensions. 2xl0 cells were stained with
PE-conjugated anti-mouse Ly- (CD8), FITC-conjugated L3T4 (CD4), and PE-
conjugated CD45R/220 (BD Pharingen, San Diego, CA). Cells were fixed with 1 
paraformaldehyde and analyzed by flow cytometr.
ENU mutagenesis
E2a-hlf heterozygous and wildtye littermate controls between the ages of 1 and 5
months were given one IP injection of ENU (50mg/kg body weight) (Sigma Chemical
St. Louis). Mice were monitored regularly for signs of disease. Upon necropsy, tissues
were fixed in neutral-buffered formalin. 4 mm sections were cut and stained with
hematoxylin and eosin by the Diabetes and Endocrinology Research Center Morphology
Core Laboratory, University of Massachusetts Medical School. Histological evaluation
was performed by Dr. Garlik, University of Massachusetts Cancer Biology Deparment.
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Figure 3: Schematic of e2a-hlfknock- in targeting construct. Ths constrct models type I
E2A-HLF translocation by fusing the e2a exons 10- 13 to the 53bp linker to HLF exon 4. f3-
globin poly A is added to ensure stability. Approximately 3.2kb of 3' homologous sequence
including exon 14 and 15 , and the pgk-NEO and HSV-TK cassettes were added to complete
the constrct.
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Figure 4. Screening of targeted e2a-hlf ES cells. Targeted ES cells were digested
overnight with EcoRI and Southern blot analysis was performed. Probing with a 3' flankng
probe yields a 18.8kb band corresponding to the wild type allele , and due to an EcoRI site
found in the NEO cassette , the mutant band drops down to 6.9kb. Similarly, probing with a
5' flanng probe yields a 18.8 kb band for the wild type allele and a 10Akb band for the
mutant allele.
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Figure 5. e2a-hlf is expressed in targeted ES cells. RT-PCR was perfonned on wild type
AB2.2 and targeted ES cells. The 370bp fragment obtained using a primer to exon 13 of e2a
and exon 4 of HLF corresponded to e2a-hlf expression.
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Figure 6. e2a-hlf knock-in mice express e2a-hlf in lymphoid tissues. RT-PCR was
performed on bone marow, spleen and thymus from wild type and e2a-hlf mice. The 428bp
fragment obtained from using primers to exon 12 of e2a and exon 4 of HLF corresponds to
expression of e2a-hlf Sequence analysis confrmed correct splicing from exon12 to exon 
of E2a.
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Figure 7. Differentiation arrest in Band T lymphocytes in e2a-hlfe2a-hlf mice. Bone marrow
cells and thymocytes were isolated from wild type and 2-3 week old e2a-hlf heterozygous and
homozygous mice and stained with anti-CD4, anti-CD8 , and anti-B220 and analyzed by flow
cytometr. The table lists the absolute numbers of B220+ bone marrow cells and DN thymocytes.
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Figure 8. No acceleration of disease upon END-mutagenesis of e2a-hlf mice. Kaplan-
Meier surval plot of ENU-treated e2a-hlf and wild type mice. A cohort of ENU-treated
e2a-hlfcohortconsisted ofn=18 , and ENU-treated wild type cohort consisted ofn=9 animals.
Mice were monitored regularly for signs of disease, and upon sacrifice, postmortem
examination performed.
CHAPTER III
ALTERATION OF THE INK4A/ARF LOCUS
CONTRIUBTES TO TALI-INDUCED LEUKEMOGENESIS
IN MICE
Introduction
T cell leukemia is caused by activation of several oncogenes including TALI
LM02, MYC, HOXII and more recently by mutations in NOTCHl (Ferrando et aI.
2004; Look, 1997; Weng et aI. , 2004). We and others have shown that misexpression of
Tall in the thymus alters thymocyte development by interfering with the expression of
E47/HB target genes including Ragl/2, Pre- , CD4, CD5 , CD3 , and the TCRa/p
chains (Herblot et aI., 2000; O'Neil et aI., 2001; O'Neil et aI. , 2004). Although Tall
induces leukemia in mice , it does so after a long latency revealing that additional genetic
events are required (Condorell et aI. , 1996; Kellher et aI., 1996). Analysis of the
INK4A/ARF locus in human T-ALL patients revealed the frequent homozygous deletion
of exon 2 , the common exon to both p16
INK4A and p14ARF genes (Cayuelaet aI. , 1995;
Cayuela et aI. , 1996; Drexler, 1998; Ferrando et aI. , 2002; Gardie et aI. , 1998; Hebert et
aI., 1994). Additional T-ALL patients exhibit alterations in the INK4A/ARF 
locus that
only affect either p16INK4A or pI4
ARF
. For example, in some cases, T-ALL patients
exhibit promoter methylation of pI 6
INK4A
, while others display specific loss ofpl4 , as
detected by loss of exon 1 P (Batova et aI., 1997; Drexler, 1998; Gardie et aI., 1998).
Ninety-two percent (13/14) of TAL I-expressing patients demonstrate deletions of exon 2
indicating the loss ofp16INK4A and p14
ARF may contribute to leukemogenesis (Ferrando et
aI. , 2002). However, the relative contribution of the two tumor suppressors to leukemia
remains unclear.
To model the INK4A/ARF deletion in mice, and to determine the 
overall
contribution ofloss ofp16Ink4a and p19
Ar to leukemia
, we mated our tall transgenic mice
to ink4a/arf-/-, p16ink4a , and pI ~rf
/- 
mice and generated cohorts of tall/ink4a/arf+/-
tall/p16ink
+/- 
and tall/pl~rf+/- We observe disease acceleration inmIce.
tall /ink4a/ arf+ tall/p 16ink4a 
+ /-
, and tall/pI Cfrf + /- mice, providing novel genetic
evidence that Tall cooperates with loss of either p l6
Ink4a or p 19Ar to cause leukemia in
the mouse.
Preleukemic studies reveal that in addition to its effects on thymocyte
differentiation, Tall expression stimulates entry into the cell cycle and thymocyte
apoptosis in vivo (O'Neil et aI. , 2004). Interestingly, mice expressing a DNA binding
mutat of Tall exhibit blocks in thymocyte development but do not show any changes in
cell cycle (O'Neil et aI. , 2001). Hence, the ability to stimulate thymocyte proliferation
appears dependent on the ability of Tall to bind DNA, but appears independent of the
effects of Tallon thymocyte differentiation. Consistent with the S phase induction
, an
increase in thymocyte apoptosis was also observed in preleukemic 
tall mice but not in
tall/ink4a/arf-/- mice, suggesting Tall induces apoptosis in a pI9
p53-depend
maner. Taken together, these studies suggest that Tall , like the c-Myc oncogene,
contrbutes to leukemogenesis by inhibiting differentiation, stimulating cell cycle entry
and activating the p19 p53 apoptotic pathway (Coppola and Cole, 1986; Dmitrovsky et
aI. , 1986; Eischen et aI. , 1999; Evan et aI. , 1992).
Results
Loss of an ink4a/arf allele cooperates with Tall to induce T cell leukemia in mice.
Human TALI-expressing T-ALL patients commonly contain deletion of the
INK4A/ARF locus , which encodes for tuor suppressors p16
INK4a and p14ARF (p19Ar in
mice) (Ferrando et aI., 2002). To test whether alteration of the ink4a/arf locus
contributes to Tall-induced leukemogenesis in the mouse, we mated our tall transgenic
mice to ink4a1arf-/- mice and established a cohort of tall/ink4a/arf+/- mice. Tall
transgenic mice develop T cell lymphoblastic leukemia with a median surival period of
350 days (Kellher et aI. , 1996). However tall/ink4a/arf+/- mice develop disease rapidly
with a median survival period of 168 days (Figure 9). Additionally, there is a highly
significant increase in disease penetrance in the 
tall/ink4a/arf+/- mice compared to tall
mice (p':0.0001). Only 28% of tall mice on a wild tye background develop T cell
lymphoblastic leukemia, whereas 100% of tall/ink4a/arf+/- mice develop disease. The
tumors that arise in tall/ink4a/arf+/- mice are identical to those observed in 
tall mice
and express both CD4 and CD8 or CD8 alone (Table 1) (Kellher et aI. , 1996; O'Neil et
aI. , 2004). Interestingly 8/11 tall/ink4a/arf+/- tumors express high CD25 levels, a
feature also observed in thymocytes expressing activated Notchl or T cell tumors arising
in Notch transgenic and e2a-deficient mice (Bain et aI. , 1997; Bellavia et aI. , 2000).
ink4a/arf alterations are detected in mouse tall/ink4a/arf+/- tumors.
Since homozygous deletion of exon 2 of the INK4A/ARF locus is commonly
observed in T cell leukemia patients (Cayuela etaI. , 1995; Cayuela et aI. , 1996; Hebert et
aI. , 1994), we examined our mouse tall/ink4a/arf+/- tumors for evidence of LOH using
PCR. Tumor DNA was isolated and genomic PCR performed to examine the 
integrty of
pl6Ink4a-specific exon la , p19 -specific exon l , and the shared exon 2 of the ink4a/arf
locus. We detected low levels of exon 2 in 2/8 tuors examined
, suggesting that the
majority of cells in the tumor had undergone LOH (Figue lOA). To confrm these
findings , Southern blot analysis was performed to confrm LOH in the 
tall/ink4a/arf+/-
tumors. Tumor DNA was digested with the restriction enzyme Pst I
transferred to a
membrane and hybridized with a cDNA probe containing par of exon la and exon 
Five of eighteen (27%) tumors exhibited evidence of LOH, as the wild type 9kb fragment
containing exon 2 was not detected in these tuors, indicating these tuors lose
expression of both p16
Ink4a and p19Ar (Figure lOB and data not shown). The reduced
levels of exon 2 observed in lanes 5 and 8 of the genomic PCR correspond to the LOH
observed in lanes 2 and 5 ofthe Southern Blot, respectively (Figure lOA and B).
Southern blot analysis detects the presence of exon 1 a (2.5kb band) and exon 2 in
the remaining taIUink4a/arf+/- tuors examined, suggesting additional mutations or
promoter methylation may affect expression of p l6
Ink4a or p 19Ar in the remaining tumors
(Figure 2B). To determine if methylation of the p16ink4a promoter occurs in
tall/ink4a/arf+/- tuors, we performed methylation-specific PCR. Genomic DNA
isolated from the tuors was treated with sodium bisulfite and methylated CpG islands
were amplified with primers specific for both unethylated and methylated region of the
p16ink4a promoter (Sharpless et aI., 2001). We find evidence ofp16ink4a methylation in 2
of 7 (28%) tall/ink4a/arf+/- tumors examined, indicating that the methylation of the
p16ink4a promoter and the subsequent loss of p16
Ink4a 
expression contributes to Tall-
induced leukemia in the mouse (Figure 10C and data not shown).
Loss of either p16IDk4a or p19Arf cooperates with Tall to induce leukemogenesis in
mice.
Human T-ALL patients frequently display homozygous loss of the INK4A/ARF
locus , but some patients demonstrate the specific loss of p14
ARF or p16INK4A
, indicating
loss of either tumor suppressor may contribute to leukemogenesis (Cayuela et aI. , 1995;
Cayuela et aI. , 1996; Drexler, 1998; Gardie et aI. , 1998; Hebert et aI.
, 1994). Similarly,
analysis of tall/ink4a/arf+/- 
tumors suggested that loss of either p19
Ar or p16Ink4a may
contrbute to disease development in the mouse. To genetically determine the relative
contribution of loss of the p16
Ink4a and p19Ar tumor suppressor genes to Tall-induced
leukemia in the mouse , we mated the tall transgenic mice to p16ink4a
/- 
or 
/- 
mice
and generated cohorts of tall/p16ink4a
+/- 
(n= 26) and tall/pl~rf+/- mice (n=28).
Consistent with the loss of p16
Ink4a and p19Arf in the tuors derived from
tall/ink4a/arf+/- mice, both the tall/pI6
k4a
+/- 
and tall/pl~rf+/- mice develop leukemia
at an accelerated rate compared to tall mice on a wild tye background (Figure 11;
p":O. OOOl for tall/plgArf+/- and p":0. 0092 for taIJ/p16ink4a
+/- 
mice). The difference in
disease kinetics observed between tall/plgArf+/- and tall/pI6ink4a
+/- 
mice was not
statistically significant (p=0.11). Interestingly, differences in tuor target cell were
observed. In contrast to tall and tall/ink4a/arf+/- mice, which display a varied
immunophenotye, there was an increased number of tall/plgArf+/- and tall/pI6ink4a
+/-
tuors were CD8 single positive (SP), suggesting either a immatue single positive (ISP)
or a CD8 SP thymocyte is the target cell in these mice (Table 1) (Kellher et aI. , 1996).
To distinguish between these possibilities, additional F ACS experiments must be
-.G:
:--
performed on premalignant and tuor cells , because ISP can be distinguished from CD8
SP by the expression ofTCR lo (Yu et aI. , 2004).
An increase in S phase cells in 
tall preleukemic thymocytes
Ink4a/arfloss in the tall/ink4a/arf+/- tuors suggests that ectopic expression of
Tall may stimulate thymocyte proliferation in vivo and thereby trigger loss of the cell
cycle inhibitor p16Ink4a or alternatively stimulate the oncogene sensor p19
determine if Tall expression alters the cell cycle in thymocytes , we performed in vivo-
BrdU incorporation studies on preleukemic 
tall mice. To examine thymocyte cell cycle
wild type and tall transgenic mice were injected intraperitoneally with BrdU, and
following a four hour rest, thymocytes were stained with anti-BrdU antibodies. In wild
tye mice, 14.52% (:. 1.4%) BrdU-positive thymocytes were detected. Interestingly, in
the tall transgenic mice , 24.47% (:. 2.8%) of cells were detected in S phase of the cell
cycle (p-c 008) (Figure 12). This 70% increase in the percentage of thymocytes in S
phase suggests that Tall expression may stimulate thymocytes to inappropriately enter
the cell cycle.
S phase induction is dependent on a functional DNA-binding domain of Tall.
Inhibition of E2A activity has been associated with increased proliferation
(Iavarone et aI., 1994; Lasorella et aI. , 1996; Pagliuca et aI. , 2000; Peverali et aI. , 1994).
Tall and the DNA binding mutant of Tall (mut Tall R188G;R189G) inhibit E2A activity
and induce leukemia in mice (O'Neil et aI., 2001; O'Neil et aI. , 2004). Therefore , the S
phase induction may be mediated by the abilty of Tall (and mut Tall RI88G;R189G) to
inhibit the transcriptional activity ofE471HB. Alternatively, the abilty to stimulate the
cell cycle may reflect the ability of the Tall/E47 or Tall/HB 
heterodimers to
transactivate the expression of novel genes.
In order to distinguish between these
possibiliti , we compared thymocyte proliferation in 
preleukemic tall and mut tall
R188G;R189G transgenic mice.
In contrast to the 24.47% (::2.8%) S phase cells
observed in tall mice mut tall R188G;R189G mice contain 15.2% (::2.
l%) cells in S
phase of the cell cycle, similar to the 15.5% (::1.5%) observed in wild tye 
littermates
(Figue 13). Thus , the ability of Tall to stimulate the cell 
cycle appears dependent on a
fuctional DNA-binding domain and suggests that Tall/E47 or 
TalllHB heterodimers
stimulate S phase by influencing gene expression. Thus
, although the DNA binding
mutat of mut Tall R188G;R189G fuctions like an Id and interacts with and inhibits E
protein fuction, it appears unable to affect cell cycle control.
Tall stimulates thymocyte apoptosis 
in vivo that is p19
Arf dependent.
Oncogenes, such as c-Myc and Ela, stimulate inappropriate entry into the cell
cycle and activate a protective apoptotic pathway that involves activation of the p 19
p53 proteins (Evan et aI. , 1992; Rao et aI. , 1992; Zindy et aI. , 1998). Consistent with this
BrdU analysis demonstrates that the S phase induction observed in 
preleukemic tall
thymocytes is accompanied by an increase in SUbGI 
cells (Figure 6). Although the
percentage of apoptotic thymocytes was variable and ranged from a 5-
10 fold increase in
SUbGI cells , the percentage of SUbGI thymocytes consistently correlated with the increase
in S phase cells observed. To test whether Tall-associated apoptosis requires an intact
ink4a/arflocus, we examined thymocyte proliferation/apoptosi
in an ink4a/arf/- genetic
background. In contrast to Tall expression in a wild type or 
ink4a/arf heterozygous
background which results in 12% SUbGI cells, only 2.
7%ofthymocytes were detected in
the SUbGI population when Tall was expressed on a 
ink4a/arf-
/- 
background (Figue 14).
Therefore , the induction of apoptosis associated with Tall activation appears 
dependent
on p19 . In contrast, the S phase cells induction is observed on both the 
ink4a/arf+/-
and ink4a/arf/- backgrounds , indicating the ability of Tall to stimulate S phase entry is
independent ofthe p16
Ink4a locus (Figue 14).
Notch and Wnt activation in preleukemi tall thymocytes
To identify how Tall activation may stimulate thymocyte proliferation
, we used
gene expression profiing to compare genes activated/repressed in 
Tall expressing
thymocytes compared to littermate controls. Consistent with the 
pertbed thymocyte
development observed in preleukemic 
tall mice and with our previous micro aray
experiments performed on 
tall DP thymocytes (O'Neil et aI., 2004), we found the
expression of multiple E4 7/HEB target genes repressed in 
tall thymocytes including
Ragl/2, pre-Ta, CD4 CD5 , and CD6 (Table 2).
Interestingly, consistent with the S phase induction, analysis of Tall-regulated
genes revealed activation of the Notch and Wnt receptor pathways. 
Specifically, Wnt5b
and its downstream target gene, c-Myc, appeared upregulated in 
tall thymocytes
compared to littermate controls (Table 2) (He et aI., 1998). In fact
, real-time PCR
analysis reveals on average a 32-fold increase in Wnt5b expression in preleukemic 
tall
thymocytes (Figure 15). Additionally, evidence of Notch activation was also detected in
preleukemic tall thymocytes with increased expression of the Notch 
1 target genes
Deltex, CD25 , and Hesl , in preleukemic tall thymocytes (Table 2 and Figue 15). As
activation of the Wnt and Notch pathways have been implicated in regulating cell
proliferation, activation of these signaling pathways in preleukemic tall thymocytes
raises the possibilty they may be responsible for the increased thymocyte proliferation
observed in tall mice.
Discussion
We and others have shown that Tall expression pertbs thymocyte development
by interfering with the expression ofE47/Heb target genes (Herblot et aI. , 2000; O'Neil et
aI. , 2004). Although Tall has been implicated in the proliferation of hematopoietic
precursors (Condorell et aI. , 1997; Green et aI., 1991; Valteri et aI. , 1998), ths study
suggests that Tall stimulates cell cycle entr in preleukemic thymocytes. 
The S-phase
induction observed in tall thymocytes durng the preleukemic phase of the disease is
accompanied by an increase in apoptosis that appears p 19 dependent. Thus , ectopic
expression of Tall shares featues with deregulated c-Myc, in that both bHLH proteins
inhibit differentiation and are capable of stimulating the cell cycle and inducing apoptosis
in vivo (Coppola and Cole , 1986; Eischen et aI. , 1999; Evan et aI. , 1992).
Independent of its effects on thymocyte differentiation, Tall stimulates the cell
cycle and this appears to be an effect of the Tall/E47 or Tall/HB heterodimers on
transcription, as no increase in S phase cells is observed in mice expressing a DNA
binding mutant of Tall. Although it remains unclear how the increase in S phase cells is
mediated by Tall , analysis of gene expression profies infuenced by Tall suggests that
the cell cycle effects may involve activation of the Wnt and/or the Notch receptor
pathways. We find Wnt5b and Myc, Deltex, Hesl and CD25a expression induced in
preleukemic tall thymocytes compared to littermate controls. Activation of either the
Notch and Wnt pathways inhibit differentiation and therefore promote self-renewal in
multiple stem cells lineages, such as: hematopoetic (Reyaet aI. , 2003; Varnum-Finney et
aI. , 2000), intestinal (Fre et aI. , 2005; Pinto et aI. , 2003; van Es et aI. , 2005), and muscle
(Polesskaya et aI. , 2003). Additionally, multiple studies demonstrate cross-talk between
these two pathways , indicating cooperativity in regulating self-renewal and proliferation
(Espinosa et aI. , 2003; Galceran et aI., 2004). In addition, recent studies suggest that the
Wnt and Notchl pathways may synergize to inhbit differentiation and promote self
renewal in hematopoietic stem cell populations (Duncan et aI., 2005), raising the
possibilty that a similar pathway may be activated in Tall-induced leukemia.
Mice expressing a DNA binding mutant of Tall develop disease, questioning the
overall biologic significance ofthe effects of Tall on the cell cycle (O'Neil et aI. , 2001).
We speculate that the inappropriate cell cycle entr and apoptosis associated with Tall
expression in vivo may provide additional selective pressure to disrupt the ink4a/arf
locus. This hypothesis predicts that ink4a/arf alterations would be observed at greater
frequencies in tumors derived from 
tall transgenic mice than in tuors derived from the
DNA binding mutant mice.
Disruption of the ink4a/arf allele is an important genetic event in Tall-induced
leukemia with both alterations of both p16
Ink4a and p19Ar observed in tall/ink4a/arf+/-
tuors. Unlike the published studies on Ef.-myclink4a/ f+/- mice which all undergo
LOH (Eischen et aI., 1999), 27% of the tall/ink4a/arf+/- tuors exhibit LOH and an
additional 28% of tuors exhibit methylation of the pl6
ink4a promoter. In contrast to the
common perception that loss of p16
Ink4a is the important genetic event in leukemia, we
provide important evidence that loss of not only p 16
Ink4a 
but also p 19
Ar cooperates with
Tall expression in leukemogenesis. Both tall/p16
k4a
+/- 
and tall/pl~rf+/- mice exhibit
an increasedpenetrance and disease acceleration compared to tall mice on a wild type
background. Therefore , the work presented in this thesis may change the common
viewpoint that only the loss ofp16Ink4a contrbutes to leukemogenesis
, and entice the field
to determine how loss of P 14Arf contributes to leukemia.
This study demonstrates that loss of p16
Ink4a or p19Ar cooperates with ectopic
Tall expression to induce T cell leukemia in mice. Studies of leukemic patients suggest
that INK4A/ARF loss is a poor prognostic indicator of ALL and consistent with these
observations, tall/ink4a/arf+/-, tall/p16ink4a
+/- 
and tall/pl~rf+/- mice rapidly develop
disease (Harison, 2001; Kees et aI., 1997; Zhou et aI., 1997). Importantly, 100% of
tall/ink4a/arf+/- mice develop T cell leukemia, making this model useful for testing the
sensitivity of these mice to curent therapies and for the development of new therapeutics.
Materials and Methods
Mice and tumor cell culture
Proximal lck- tall and mut tall R188G; R189G mice have been described previously
(Kellher et aI. , 1996; O'Neil et aI. , 2001). ink4a/arf p16ink4a and plgarf deficient
mice have been described previously (Kamijo et aI. , 1997; Serrano et aI. , 1996; Sharpless
et aI., 2001) and obtained from the Mouse Models of Human Cancers Consortium
(MMCC). Cohorts of tall/ink4a/arf+/- (n=27), tall/p16ink4a
+/- 
(n=20), and
tall/pl~rf+/- (n=26) mice were established and monitored daily for signs of disease.
Kaplan-Meier analysis was performed on, tall/ink4a/arf+/- mice tall/p16ink4a
+/- 
mice,
and tall/pl~rf+/- mice and compared to 
tall mice on a wild type background. All mice
are maintained on a FVBIN genetic background.
Flow Cytometry
Primary tumor cells were stained with PE-conjugated anti-mouse Ly-2 (CD8), FITC-
conjugated L3T4 (CD4), and PE-conjugated CD25 antibodies (BD Pharmingen, San
Diego, CA) and analyzed using flow cytometr. For in vivo-BrdU-incorporation assays
four- to six-week old tall, mut tall (R188G;R189G), tall/ink4a/arf+/- and
tall/ink4a/arf/- mice were injected intraperitoneally with lmg bromodoxyuridine (BrdU)
and allowed to rest for 3 hours. The mice were injected again with lmg of BrdU and
allowed to rest for 1 h. Thymocytes were isolated and 2xl0
6 cells were stained with anti-
mouse Ly-2 (CD8), FITC-conjugated L3T4 (CD4) antibodies. The thymocytes were then
fixed, permeabilized and stained with APC-conjugated anti-BrdU antibody and 7-amino-
actinomycin D (7-AAD) as described in APC BrdU Flow kit (BD Pharingen). Values
are provided as mean :i stadard deviation, and p-values are from Student's t-test
analysis.
Real-time PCR
Wnt5b real-time primer sequences were obtained from Georg A. Hollander 5' -GGC-
A TT -GGG-A TG-GGT - TGA-GG-3' and 5' - GGA-GTT -GGC-GTC-AGT -CAG-CAG-
Primers for c-Myc (5' CTG-TTT-GAA-GGC-TGG-ATT-TCC- 3' and 5' GTC-GTG-
GCT-GTC-TGC-GG- ), Deltex (5' TGC-CTG-GTG-GCC-ATG-TAC- 3' and 5'
GAC-ACT-GCA-GGC-TGC-CAT- ), and Notchl (5' AAG-AGC-TGC-GCA-AGC-
ACC-3' and 5' TAG-ACA-ATG-GAG-CCA-CGG-ATG- ) were designed using Primer
Express (Applied Biosystems). Relative quantities of mRNA expression were analyzed
using QRT-PCR in the presence of SYBR green (Applied Biosystems ABI Prism 7300
Sequence Detection System, Applied Biosystems). For the normalization of each sample
the expression level of the gene was divided by that of p-actin. The relative expression
level was determined by comparing the normalized value UP-actin) to that in the
reference sample (another normal tissue) included in the same reaction.
Microarray Analysis
Thymocytes were pooled from four age-matched (4 weeks) wild type and tall mice
RNA extracted using Trizol reagent (Invitrogen, Carlsbad, CA), and purified using
Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). RNA was hybridized to Affymetrix
Mouse Genome 430A 2.0 arrays (Affymetrix, Santa Clara, CA). Data sets were analyzed
using Rosetta Resolver by Manoj Bhasin (Dana Farber Cancer Institute).
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Figure 9. Disease acceleration in tall/ink4a/arf+/- mice. Kaplan-Meier surival plot of 
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and tall/ink4a/arf+/- mice is shown. The 
tall cohort consisted of n=64 animals , and the cohort
of tall/ink4a/arf+/- mice consisted of n=27. Tarone-Ware statistical analysis demonstrates a
highly statistically significant difference in surival between the tall transgenic mice and the tall
transgenic mice on the ink4a/arfheterozygous 
background (P ':0.0001).
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Figure 10. Alterations in the ink4a/arf locus in tall/ink4a/arf+/- tumors. A) To
examine the integrity of the ink4a/arf locus, genomic DNA was isolated from
tall/ink4a/arf+/- tuors and screened for the presence of exon la, exon Ip, and exon 2
using PCR. B) To fuher analyze the status of exon 2, genomic DNA from
tall/ink4alarf+/- tuors was digested with Pst I transferred to a membrane, and probed
with cDNA probe corresponding to exon la and exon 2. C) To analyze the methylation
status of the p16ink4a promoter, bisulfite-treated tall/ink4a/arf+ /- tuor DNA was
amplified using primers specific for the p16ink4a methylated promoter and p16ink4a
unmethylated promoter as described in (Sharless , Bardeesy et al. 2001).
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Figure 11. Disease acceleration in tall/p16inMa
+/- 
and tall/p19 f+/- mice. Kaplan-Meier
survival plot of tall, tall/ink4a/arf+/-, tall/p16
ink4a
+/-
and tall/plgaf+/- mice is shown.
Tarone-Ware statistical analysis demonstrates a highly statistically signficant difference in
survival between the tall transgenic mice and the tall/p16ink4a 
mice (p = 0092), or the
tall/p19 f+/- mice (p=0.00001)
Table 1. Immuno henotype of tall/ink!arf+ , tall 16+/-, and tall I9+/- tumors
Animal
Survival
Number Genotyp CD8 CD4, CD8 CD25 Phenot
2869 tall link! arf+ 
CD8 SP
2902 tall /ink/ arf+ 
168
2906 tall /ink/ arf+ 
134
2912 tall /ink/ arf+ CD8 SP
177
2913 tal I link! arf+ 
130
2914 tal I link! arf+ 
139
3199 tall /ink/arf+ CD4 SP
126
3470 tall /ink/arf+ 
3483 tall link! arf+ 
CD8 SP
3569 tall link! arf+ 
3570 tall /ink!arf+ 
, CD8 SP
4432 tall/pI 6+/- 
CD8 SP 115
4436 tall /p16+ 
109
4437 tall/p16+/- CD8 SP 123
4438 tall /p 16+ CD8 SP
123
4439 tall/pI 6+/- CD4SP
108
442 tall/p16+/- CD8 SP 120
5406 tall /p 16+ 
CD8 SP 100
5409 tall /p 16+ 
CD8 SP 150
5415 tall /p16+ 
CD8 SP
4393 talI/pI 9+/- 
CD8 SP
5129 tall/pI 9+/- 
CD8 SP
5131 tall/p19+/- 102
5138 tall/p19+/- CD8 SP
5519 tall /p 19+ /- CD8 SP
, DP
5521 tall /p19+ 
CD4 SP 109
5522 tall/p19+/- CD8 SP
5587 tall /p 19+ /- CD8 SP
, DP
5588 tall 19+ 
CD4 SP
Tumors were stained with antibodies to CD3 , CD4, CD8 and CD25 and analyzed by flow 
cytometr.
Tumors were considered ositive if;;1 0% of the tumor stained for that antibod
tal 
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Figure 12. Increase in S phase cells in tall premalignant thymus. To measure
thymocyte proliferation in vivo BrdU-incorporation analyses were performed on four-
week old wild type and tall mice. The mice were inj ected intraperitoneally twce
with Img BrdU, and four hours later, the thymocytes were stained with an anti-BrdU
antibody and analyzed by flow cytometr. Tall thymocytes show a statistically
significant increase in BrdU-positive cells compared to wild type (p=0.0025). A
representative of five independent experiments is shown.
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Figure 13. Increase in S-phase cells is observed in 
tall transgenic mice but not in
mice expressing a DNA binding mutant of mut tall (R188G;R189G). To determine if
DNA-binding domain is essential for the increase in S-phase cells in vivo BrdU-
incorporation experiments were performed on wild type, tall transgenic
, and tall
R188G;R-189G transgenic mice. Mice were injected IP twice with 1 mg of BrdU and
following a 4 hour rest, thymocytes were stained with antibodies to BrdU and analyzed by
flow cytometr. Mut tall (R188G;R189G) mice have decreased levels of BrdU-
positive
cells compared to tall thymocytes (p= 02). Three wild type
, three tall and three mut
tall (R188G;R189G) transgenic animals were analyzed.
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Figure 14. Thymocyte apoptosis in 
tall but not tall/ink4a1arf-
/- 
thymocytes. To determine
if Tall activates the p19Ar p53 pathway, in vivo BrdU-incorporation analyses were performed
as described on wild type tall, tall/ink4a/arf+/- and tall/ink4a/arf/- mice and analyzed by
flow cytometr The increase in S phase cells was accompanied by an increase in subG 1 cells
and this Tall-mediated increase in subGl cells is not observed in the absence of the ink4a/arf
allele. A representative of thee independent experiments is shown.
Table 2: Genes Found Altered in ta/1 Thymocytes
Description of gene (accession number) Fold change
CD5 antigen (NM 007650) -5.4
Rag2 (NM 009020) -4.CD6 antigen (U12434) -4.4
Bcl- (NM 009743) -4.4
ROR-gamma (AJ132394) -
CD4 antigen (NM 013488) -
Id2 (NM 010496) -
Bcl2 (NM 009741) -
pre T-cell antigen receptor alpha (NM 011195) -
Rag1 (NM 009019) -Myc (BC006728) +2.IL2R alpha (AF054581) +2.Deltex 1 (AB015422) +3.
Cdk6 (NM 009873) +3.
Wnt5b (NM 009525) +8.
p-value
05E-
36E-
57E-
31 E-
80E-
00627
96E-
46E-
20E-
52E-
92E-
00216
00037
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Figure 15. Activation of Notch and Wnt pathways in tall premalignant thymocytes. A)
Premalignant tall thymocytes express increased levels of Wnt5b, c-Myc, Deltex and Hesl.
To validate activation of Notch and Wnt pathways, real-time PCR was performed on 4 week
old wild type and tall thymoctyes. B) Tall thymocytes express increased levels of CD25.
To assay CD25 levels, wild type and tall premalignant thymocytes were stained with anti-
CD25- , stained and analyzed by flow cytometr. C) Increased CD25 expression is seen in
all subsets of Tall thymocytes (continued on page 82). Wild type and tall thymocytes were
stained with CD4, CD8 , CD25 , and analyzed by flow cytometr to determine CD25 expression
within DN , SP , and DP subsets.
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CHAPTER IV
ACTIV A TION OF THE NOTCHI P THW A Y COMMON IN
TALI-MEDIATED LEUKEMOGENISIS IN THE MOUSE
Introduction
Tall is a bHLH transcription factor that is found misexpressed in the thymus in
60% of T-cell acute lymphoblastic leukemia (T-ALL) patients (Bash et aI., 1995).
Significantly, TALI-expressing T-ALL patients exhibit a less favorable prognosis, with a
five year survival of 43%, indicating additional therapies are crucial for TALI leukemic
patients (Ferrando et aI. , 2002). To model the misexpression of TALI , we previously
generated lck- tall transgenic mice, which develop T cell leukemia with a long latency of
350 days , signfying that additional genetic events are required (Kellher et aI. , 1996).
Notchl is a member of an evolutionarily conserved family of proteins essential
for cell fate determination. Notchl is a transmembrane receptor that binds to ligands of
the Jagged- and Delta- family. Upon ligand binding, two successive cleavage events
occur, which allow the intracellular domain of Notchl (Notch ) to translocate to the
nucleus (De Strooper et aI. , 1999). Within the nucleus , Notch binds to and displaces the
corepressors from CSL/RP- , thereby relieving transcriptional repression (Kurooka
and Honjo , 2000; Oswald et aI., 2001). Notch then recruits Mastermind (MAML), and
. the coactivators p300 , GCN5 , and PCAF to activate transcription of target genes such as
Hesl , Deltex, and preT-alpha (Deftos et aI. , 1998; Kurooka and Honjo , 2000; Oswald et
aI. , 2001).
Notch 1 was first implicated in leukemogenesis through the t(7;9)(q34;q34.
translocation, which juxtaposes the NOTCHI gene to the TCRp locus (Ellsen et aI.
1991). This translocation, associated with less than 1% of T cell leukemic patients (Ma
et aI. , 1999), leads to a trcated, constitutively active allele capable of signaling in a
ligand-independent manner. The leukemogenic properties of this constitutively active
Notch protein has been demonstrated in vitro, II bone marow transplantation
experiments in mice , and in NotchIC-expressing transgenic mice (Capobianco et aI.
, 1997;
Deftos et aI. , 2000; Pear et aI. , 1996; Robey et aI. , 1996). A recent study demonstrates
NOTCH 1 activation and HES 1 expression, in all leukemic samples tested (Chiaramonte
et aI., 2003). In addition 56% of T-ALL patients and specifically 39% of TAL1-
expressing patients exhibit mutations withn the heterodimerization 
(00) and/or PEST
domains of NOTCH 1 (Weng et aI. , 2004). Together these studies suggest that 
activating
NOTCH 1 mutations may be an important event in T cell leukemogenesis.
In this study, we used retroviral insertional mutagenesis to identify genes that
cooperate with Tall to induce leukemia in mice. Interestingly, 32% of infected 
tumors
harbored Moloney Murine Leukemia Virus (MoML V) integrations in the midregion of
the notchl gene, which would lead to constitutive active allele. The 
tuors remain
dependent on Notchl signaling as Notchl target genes, Hesl and Deltex
, remain
expressed. Consistent with Tall cooperating with 
Notchl activation in leukemogenesis
spontaneous tall tuors also commonly activate the Notchl pathway, as observed
through increased levels of cleaved intracellular Notch, and the induction of Notch target
genes. In addition, Notchl activation in tall tuor cell lines frequently conferred
sensitivity to y-secretase inhibitors. Additionally, mutational analysis of Notchl 
in tall
tumors revealed frequent mutations in the HD andlor PEST domains.
To identify Notch target genes responsible for arest and apoptosis
, we
developed a doxycycline (dox)-regulated Notch leukemic cell line by converting to
cultue tumors arising in EJ1tTAINotch /tall triple transgenic mice. 
Doxycycline
treatment results in an increase in SUbGl and cells , indicating Notch provides both
proliferative and an anti-apoptotic response in leukemic cells. We performed
micro array analysis on this conditional Notch ALL cell line to determine the Notch
taget genes that may contrbute to leukemogenesis. In addition to the regulation of many
known Notch target genes, new putative target genes were identified. 
Interestingly,
Ingenuity pathway analysis and quantitative real-time PCR demonstrated activation of the
Myc pathway in the presence of Notch . The activation of Myc provides insight as to
how Notch may contrbute to leukemogenesis
Results
The Notchl locus is a common insertion site in MoMLV-
infected mut ttill
(R188G;R189G) tumors.
To identify oncogenes that cooperate with Tall, we performed retroviral
insertional mutagenesis. Wild tye tall, or mut tall (R188G;R189G) 
transgenic
neonates were injected with 50/-I of Moloney Murine Leukemia Virus (MoML V) 
in the
presence of 8/-g/ml polybrene. As expected, infection with MoML V greatly accelerates
the rate of disease , with a median surival latency of 81 days for 
tall mice and 61 days
for mut tall (R188G;R189G) mice (Figue 16A and 
data not shown). In addition
MoML V - infected tall mice and mut tall (R188G;R189G) 
mice both develop leukemia
with complete penetrance. Moreover, MoML V -infected wild type mice also 
develop
disease with a median survival of approximately 180 days
, which is signficantly longer
than MoML V - infected tall or mut tall (R188G;R189G) 
mice (Feldman et aI. , 2000).
We utilized inverse PCR (IPCR) to clone the region adjacent to the MoMLV
integration in the genome. Subsequent sequence analysis of one cloned genomic clone
determined that MoML V integrated into intron 28 of the notchl 
gene , likely resulting in a
constitutively active intracellular Notchl protein. The previous connection between
NOTCH 1 activation and leukemia prompted us to fuher investigate notchl 
in Tall-
mediated leukemia. To determine the prevalence of 
notchl integrations in MoML V-
infected mut tall R188G;R189G tuors , we performed Southern blot screening on the
remaining MoML V -infected tuors. We digested genomic DNA 
isolated from
MoML V - infected mut tall R188G; R189G tuors with EcoR V, transferred to 
membrane, and probed with a notchl cDNA probe. The probe 
contains notchl cDNA
exons 22- , or cluster region I, which has previously been shown to be a common site of
integrations in retroviral 
mutagenesis in MMTvD /myc 
and e2A/pbxl transgenic mice
(Feldman et aI. , 2000; Girard et aI. , 1996). Thirt-two percent 
(8/25) of the MoML V-
infected mut tall Rl88G; R189G 
tumors contained integrations in the cluster region I 
the notchllocus (Figure l6B). Surrisingly, 
additional Southern blot screening showed
0/18 tuors contained MoMLV integrations in the 3' cluster region II
, which deletes
negative regulatory the PEST domain (Figure l6B). This suggests that during MoML V-
induced tall leukemogenesis , there appears to be a preferential activation of Notchl by
MoML V integration into the midregion ofthe 
notchl rather than the 3' PEST domain.
To determine if integration of MoML into the notchl allele increased
intracellular Notchllevels, we performed Western blot analysis on MoML V -
infected mut
tall Rl88G;Rl89G tuors (Figue 16C). Tumors that contain 
notchl integrations (lanes
, 5 , and 6) display increased levels of Notch compared to wild type thymocytes (lane
8) or MoML V -infected tumors without Notchl integrations (lanes 1
, 3 , 4 , and 7). Yet
not all mut tall tuors containing MoML V integrations in notchl 
overexpressed
Notch 1 IC. To fuer determine ifthe Notchl pathway was activated in these tuors
, we
examined expression of known Notchl target genes
, Hesl and Deltex by performing RT-
PCR. Compared to wild type thymocytes and premalignant 
tall thymocytes , MoML V -
infected mut tall Rl88G;R189G 
tuors exhibited increased levels of Hesl and Deltex
expression, suggesting that tumors remain dependent on Notchl 
signaling (Figure 16D).
Notchl activation is common in spontaneous 
tall tumors
Notchl has been previously identified as a common retroviral 
integration site
(CIS) (Shen et aI., 2003; Suzuki et aI., 2002). Therefore
, to determine if the notchl
integrations contributed to Tall-mediated leukemia or were only identified through this
locus being a CIS, we next wanted to determine if 
tuors that spontaneously arise in the
tall transgenic mice also exhibit Notchl activation. To assay 
activation of the Notchl
pathway, we performed RT-PCR on 12 tall tuor cell lines, assaying for Hesl and
Deltex expression. Ten 
tall tuor cell lines (83%) demonstrated increased levels ofHesl
and Deltex , signifying that Notchl is commonly activated in 
tall tumors (Figure 17 A and
data not shown). The 
tall tuor cell lines remain dependent on Notchl signaling since
pharmacologi inhibition of Notch 1 with y-secretase inhibitors results in 
/GI arest and
apoptosis. In fact 12/18 (67%) of the tall tumor cell lines display sensitivity to DAPT
, a
y-secretase inhibitor (Figure 17B). To confirm that y-secretase inhbitor treatment
interferes with Notchl signaling in the 
tall ALL lines, we assayed Hesl and Deltex
expression by RT-PCR following DAPT treatment. There is a 
significant reduction of
Hes 1 and Deltex expression levels following a 24h DAPT treatment
, and following a 48h
DAPT treatment, negligible levels of Hesl and Deltex remain (Figure 
17C). Strikingly,
Western blot analysis demonstrated increased levels of Not ch
in 100 percent (18/18) of
tall tumor cell lines examined, and a 48h DAPT treatment in the 
tall ALL lines
significantly decreased Notch protein levels (Figure 18A and B). The Western blot also
demonstrates Notch running with greater mobility in some 
tall ALL lines , which is
consistent with the presence of trucations of the PEST domain (asterisk in Figure 18A).
Together, this data indicates that activation of the 
Notch pathway is a common
secondar event in spontaneous tall tuors.
Development of Dox-regulated Notchl T -ALL line
Although some Notchl target genes have been identified, the target genes are
likely to be cell-type specific , and remain unclear . f r leukemic cells. To identify 
the
signal Notchl activation provides durng leukemogenesis, we developed a dox-regulated
NotchIC T -ALL cell line. To develop this system, we mated the tall 
transgenic mice to
EJ1tTA/NotchIC bitransgenic mice, isolated tuors arising in the EJ1tTAlNotch
/tali
mice , and adapted them to culture. Tumors isolated from tall mice readily adapt to cell
cultue; 89% (8/9) of tall tumors rapidly convert to cultue (Kellher et aI., 1996).
Conversely, of 14 EJ1tTA/Notch /tall tuors isolated
, only one tumor successfully
converted to cultue and confirmed responsive to doxycycline. Western blot analysis 
the dox-regulated Notch ALL line demonstrates that following 24 hr dox treatment
NotchIC levels decrease to levels seen in wild type thymocytes (Figue 19A). 
Two
additional EJ1tTA/Notchlc/tall tuors also converted to culture, but failed to regulate
Notch in a dox-dependent maner (data not shown).
To confirm the Notch signaling pathway was intact in this cell line and
fuctioning in a dox-dependent manner, we performed RT-PCR to assay Hesl and Deltex
expression levels following dox treatment. There is 
a significant reduction of Hes 1 and
Deltex expression levels following an l8h dox treatment and a complete absence
following 24h dox treatment (Figure 19B). This 
indicates the dox-regulated Notch
ALL cell line regulates the Notch signaling pathway in a dox-dependent manner.
Phenotype 
of Dox-regulated Notchl T-ALLline
Human leukemic T-ALL cell lines exhibit both a GI 
arest and an increase in
apoptosis following pharmacologic inhbition 
of Notchl pathway by treatment with y-
secretase inhbitors (Weng et aI., 2004; Weng et aI. , 2003). To test the 
possibility that
Notch expression is providing either an anti-apoptotic and/or proliferative signal
, we
performed cell cycle analysis of the dox-regulated 
Notch T -ALL cell line in the
presence and absence of doxycycline. Following 24h dox treatment
, there was no
significant change in cell cycle profies (data not 
shown). However, following 72h dox
treatment, there is a statistically significant increase in cells in the subG
phase of the cell
cycle, indicating an increase in cells undergoing apoptosis (p=0.
0009) (Figue 20A). In
addition, the dox-treated cells demonstrate a 
/GI cell cycle arrest. After electronically
gating out SUbGI cells, a 22% increase in cells in 
/GI phase of the cell cycle is
observed (p 002) (Figure 20B). This demonstrates that Notch
is providing both a
proliferative and an anti-apoptotic signal in this conditional Notch
system. The cell
cycle profile following a 72h dox treatment is similar to cell cycle 
profiles observed
following treatment with the y-secretase inhbitor
, DAPT, in sensitive mouse and human
ALL cell lines (Figure 17B and (Weng et aI. , 2003)).
Notchl signaling is essential for normal development of T 
lymphocytes.
addition to influencing 
versus y8 T' cell development, overexpression of Notch
also
promotes the matuation of CD4+ and CD8+ SP thymocytes (Deftos et aI., 2000; Robey
et aI. , 1996; Washbum et aI., 1997). To test the possibility that Notch
expression alters
CD4 and CD8 co-receptor expressio in our system, we 
assayed CD4 and CD8
expression following a 72h doxycycline treatment. 
We observe a significant increase in
the mean fluorescence intensity (MI) of CD4-FITC following dox treatment
, indicating
NotchIC expression is associated with decreased expression of the 
co-receptor CD4
(p=0.001) (Figue 21A; MFI=8.2:J1.52 for -dox compared to MFI=19.03:J1.03 for +dox).
The repression of CD4 may be explained by the induction of the Notchl 
target gene
Hesl , which binds to the CD4 silencer in to repress CD4 transcription (Allen et aI.
2001). Alternatively, the inhibition of E2A by Notch may indirectly decrease the
transcription of CD4 , an E2A target gene (Bain et aI., 1997; Sawada and Littman
, 1993;
Zhuang et aI. , 1996). Conversely, we observe no significant change in CD8 expression
levels following dox treatment, indicating 
Notch does not affect CD8 expression
(Figure 21A).
Thymocytes from Notch 1 IC and Notch3 transgenic mice exhibit increased levels
of CD25, the high-affnity IL-2Ra , indicating that inappropriate Notch
signaling either
induces or fails to repress CD25 (Bellavia et aI., 2000; Deftos and Bevan, 2000).
Additionally, expression of Notch 1 
IC inCD4+ SP T cells induces all chains ofthe IL-
complex and enhances proliferation (Adler et aI. , 2003). Consistent with these results
the immunophenotype of the 
Eu/tTA/NotchIC/tall tumors were either CD8+ SP or DP
and expressed moderate to high levels of 
CD25 (data not shown). To determine if
NotchIC regulates CD25 expression in the dox-regulated Notch
ALL cell line, we
stained cells with antibodies against CD25 and performed F ACS analysis.
The
expression of CD25 decreases drastically in the absence of Notch
signaling, displaying
over an II-fold decrease in the MFI of CD25-PE following a 48h dox treatment (Figure
2lB). Furhermore, pharacologic inhbition of Notch in tall cell lines with DAPT
treatment also resulted in a decrease in CD25 expression levels (data not shown).
Notcb target genes in T -ALL cell line
To determine what signal Notch is providing during leukemogenesis, we
performed an Affmetrix microaray experiment comparing Notch
ALL line.
Following a 24h mock or doxycycline 
(2!Jg/ml) treatment of the dox-responsive Notchl
cell line, RNA was isolated from and hybridized Affyetrx 430A 2.
0 microarrays
which contain 14 000 genes. The Rosetta Resolver System was used for normalization
and statistical analysis. To narow down the data set, we utilized a cut off 
p-value of
-cO.005 , and greater than a 2.5 fold change. A parial list of putative and known Notch 
1 IC
target genes is shown in Table 4, and a more comprehensive list can be found in
Supplemental Data 2. As expected, with continuous expression of Notch
, many known
Notch 1 target genes are expressed at high 
levels: Hes 1 , Deltex, IL2Ra, and pre-
Ta receptor (Adler et aI. , 2003; Deftos et aI., 2000) (Table 1). In addition, multiple genes
implicated in Notch signaling were also found upregulated in the absence 
doxycycline , for example , Notch3 , Adam 19 (Meltrin ), and members of the Interferon
200 gene family (Table 1) (Adler et aI. , 2003; Deftos et aI. , 2000; Huang et aI. , 2004). In
addition, the array demonstrates an increase in IL- lO levels but not IL-
, both of which
are reported upregulated following Notch activation by Jaggedl (Amsen et aI. , 2004).
Expression of Notch in this dox-regulated T-ALL cell line appears to 
induce
multiple genes implicated in regulation of Notchl signaling. For example
, Deltex is
highly expressed in the absence of doxycycline , and has been proposed to antagonize or
.."
promote Notchl fuction depending on the model system (Izon et aI. , 2002; Matsuno et
aI., 1995). In addition, Notch induces expression of both Nf2r2 
(nuclear receptor
subfamily 2, group 2) and Nrar (notch regulated anin repeat protein). Nrar inhibits
Notch function in a CSL-dependent manner, and is capable of inhibiting thymocyte
development in vivo (Kebs et aI. , 2001; Yun and Bevan, 2003). Nf2r2 has recently been
im.plicated in the inhbition of Notch 1 
IC fuction in angiogenesis (Gridley, 2001; You et
aI. , 2005). Together, this suggests that Notch may induce genes that negatively regulate
its transcriptional activity or fuction.
Ingenuity pathway analysis revealed c-Myc was transcriptionally activated and
many downstream c-Myc target genes were either induced or repressed upon Notch 1
activation (Table 4). Furermore, quantitative real-time PCR demonstrated c-Myc
mRNA transcripts are elevated 10-fold in the presence Notch compared to when
NotchIC is suppressed by a 24h dox treatment (lO.03:i 007, p= 002, data not shown).
Consistent with this, Satoh et. aI. demonstrated ectopic expression of Notchl induced c-
Myc expression in HSC , and NotchllCSL activated the c-Myc promoter in a 
reporter
assay (Satoh et aI. , 2004).
I u
Discussion
Retroviral insertional Mutagenesis (RM) demonstrates that expression of Tall
cooperates with Notchl activation to induce T-ALL. We observed MoMLV integrations
in the notchl allele in (8/35) MoML V - inected mut tall (R188G;RI89G) 
tumors. All of
the notchl integrations were found in cluster region I, which contains the LNR and
EGFR repeats. Conversely, no integrations were observed in cluster region II, located
within the PEST domain. Previous retroviral insertional mutagenesis screens of both
E2A-Pbxl and MMTvD/myc transgenic mice detected MoMLV integrations in notchl,
indicating that similar to human T-ALLpatients, activation of Notch 1 is common durng
T cell leukemogenesis in the mouse (Feldman et aI. , 2000; Girard et aI. , 1996; Weng et
aI. , 2004). However, Notchl has been previously identified as a common integration site
(CIS) durng retroviral Insertional Mutagenesis (RIM)(Shen et aI., 2003; Suzuki et aI.
2002).
Interestingly, activation of Notchl is also common in spontaeous tall tuors.
This confirms that the identification of notchl integrations cooperate with Tall 
leukemogenesis, and is not a consequence of being a CIS. All tall ALL lines tested
express increased levels of cleaved Notchl protein, and 80% show activation of Notchl
pathway through upregulation of Hes 1 and Deltex. This is consistent with the high
percentage of tall tuor cell lines that display sensitivity to y-secretase inhibitors.
Furhermore, recent evidence revealed over 74% of tall primar tumors contain
mutations in either the HD domain or PEST deletions in Notch!. Interestingly, the
majority of mutations observed in tall 
tumors are in the PEST domain, ultimately leading
to a premature stop and trucation of the PEST domain.
percentage of the tall tuor cell lines exhbit sensitivity to y-secretase
inhbitors without harboring Notchl mutations. Ths result 
suggests additional members
of the Notchl signaling pathway may be mutated. For 
example, mutations within the
LNR domain could result in increased Notchl activity. Point mutations in the 
LNR
domain of C. Elegans lin- 12 induces a gain of fuction phenotye
, or deletion of the
LNR domain induces Notchl activation (Greenwald and Seydoux
, 1990; Rand et aI.,
2000). In addition, 5' deletions of notchl lead to transcriptional initiation at 
crytic start
sites and result in alternate transcripts
, likely resulting in Notchl proteins lacking the
extracellular domains and thereby signaling in a ligand-
independent maner (Tsuji et aI.
2003). Additionally, mutations in the other members of the Notchl signaling pathway
could result in Notchl activation. For example, inactivating mutations in the Notchl E3
ligases, Sel-l0 or Itch, could result in increased stability and 
therefore enhanced
signaling. Similarly, mutation of other negative regulators, Numb or 
Nrar, could also
result in Notchl activation. Furhermore, increased concentrations of 
ligand, or
mutations in proteins modulating Notchl response to ligand binding, such as the Fringe
family of glycosyltransferases , may also result in Notchl 
activation. Another potential
way to induce Notch activation may be the deletion ofmicroRNAs (miRNAs). 
A recent
discovery suggests miRNAs may regulate Drosophila Notch and Notch target 
genes;
ectopic expression of Notch target-regulating miRNAs results in a Notch loss of 
fuction
phenotype (Lai et aI., 2005). A link between deletion of miRNA clusters and human
leukemia has previously been demonstrated; the loss of miR-
15a/miR- 16 cluster is
associated with B-CLL and mantel cell lymphoma (Calin et aI. , 2002; Juliusson et aI.
1990; Stilgenbauer et aI., 1998). miR-34 was computationally 
determined to regulate
vertebrate Notchl and Delta (Lewis et aI., 2003). Therefore, the loss of miR34 may be
another potential mechanism to induce Notch activity.
This dox-regulated Notch ALL line provides multiple advantages over other
experimental systems to examine the fuction of Notchl in 
leukemogenesis. For
example , although y-secretase inhibitors are commonly used to inhibit the cleavage and
activation of Notch (De Strooper et aI. , 1999), they do not specifically inhibit Notch
signaling. y secretase inhibitors also inhibit the well characterized cleavage of amyloid
precursor protein, ErbB4 , CD44, Growth hormone receptor, and N- and E-cadherins
(Cowan et aI. , 2005; Haas et aI. , 2005; Lammich et aI. , 2002; Ni et aI. , 2001). This
growing list of transmembrane proteins cleaved by y secretases complicates the
interpretation of analyses performed on cells treated with y-secretase inhbitors.
However, doxycycline treatment of this conditional Notch cell line specifically inhibits
NotchIC expression levels. Therefore, this system provides an opportunity to identify
Notchl-specific genes.
Another advantage of this dox-regulated T-ALL system is ilustrated by the fact
that Notchl signaling differs depending on cell type and context. For example
, Notchl
signaling leads to growth arrest and differentiation in keratinocytes , but induces S-
phase
induction in rat kidney epithelial cells (Rangarajan et aI., 2001; Ronchini and
Capobianco , 2001). Therefore , to determine the signal Notchl activation provides during
leukemogenesis , it is essential to interrogate Notchl signaling in the appropriate cell type.
Therefore this T -ALL cell provides the ideal context to investigate the fuction of Notch 1
in leukemogenesis.
Microaray analysis on this dox-regulated Notch T -ALL line demonstrated the
upregulati of numerous known Notch target genes
, fuher validating the system.
Nrar, Notch3, Hesl , CD25 , ADAM19, Deltex, ILlO, lR4
, Egrl , and preTa have been
shown in different cell systems to be Notchl-regulated genes (Adler et aI.
, 2003; Amsen
et aI., 2004; Deftos et aI., 2000; Huang et aI., 2004). Ingenuity pathway 
analysis
ilustrated the alteration of various c-Myc-induced genes:
Mina, Srm, Adm, Ly6a
Gadd45y, and Fabp4. The increased levels of c-Myc transcript levels were 
further
validated using quantitative real-time PCR. The regulation of c-
Myc by Notch has been
previously implicated in HSC cells (Satoh et aI., 2004), and we have preliminar
chromatin immunoprecipitati suggesting that Notch 1 
IC and CSLIRP-Jk bound to the
promoter regions of the c-myc promoter (Vishva Shara, preliminary 
results).
Additional preliminary data suggests that 
ectopic expression of c-Myc in the dox-
regulated Notch cell line may rescue some of the GI 
arest and apoptosis following dox
treatment.
NOTCH 1 activation has been implicated in numerous types of 
cancers and
treatment with GSI has been shown to induce apoptosis or differentiation 
in vitro and 
vivo. Therefore , GSI may prove to be an effective adjuvant therapy for the varous types
of cancer. Fortunately, GSI are currently in phase I/II clinical trials for 
treatment of
Alzheimer s patients and appear to have no severe toxicity. 
In addition, Drs. Miele and
Nickoloff indicate that GSI may synergize with other chemotherapeutic agents such as
cisplatin, MG 132, or Paclitaxel, allowing lower doses of 
combined chemotherapeutic
treatments, and therefore less severe side-effects (University of Ilinois 
Technology
ReffCX063).
Recent mathematical analysis predicts that a minimum of 3 targeted drugs of
different specificities should ultimately be used to prevent 
tuor resistance (Komarova
and W odarz, 2005). Therefore, additional Notch inhibitors need to be 
developed.
Interestingly, imatinib has been shown to inhbit the 
cleavage of Amyloid-(3 (A(3)
peptides in vitro but inhbiting Notch cleavage was not extensively examined. (Netzer et
aI. , 2003). In addition, antisense Notch and anti-Notch monoclonal antibodies have been
successfully used to inhibit Notch signaling 
in vitro (Garces et aI. , 1997; Weijzen et aI.
2002; Yasutomo et aI. , 2000). Additionally, soluble Notch decoys have been described
that sequester Notch ligands and therefore prevent ligand-receptor binding and Notch
activation (Garces et aI. , 1997; Nickoloff et aI. , 2002). Another possible option is the
development of a small molecule inhibitor that would bind intracellular Notch
, inhibiting
the Notch-CSLIRB-JK interaction, or inhibiting the recruitment of Mastermind.
The high percentage of 
tall tumor cells that contain 
notchl mutations (74%),
andlor display sensitivity to y-secretase inhibitor (GSI) treatment (67%), prompts us to
determine if disease kinetics are altered when 
tall transgenic mice are treated with y-
secretase inhibitors. Therefore , important ongoing experiments are to determine if 
tall
tumors regress following GSI treatment. It is expected from the high percent of 
tall
tuor cells that display sensitivity to GSI treatment in vitro that upon GSI treatment of
moribund tall mice , disease will regress. It wil be interesting 
to determine if the tumors
regress through the induction of apoptosis or differentiation. Our 
in vitro data predicts
tall tuors may regress by undergoing apoptosis. Additionally, GSI treatment of
malignant melanoma cell lines rapidly induced apoptosis (Qin et aI. , 2004). However
since Notchl activation inhibits the differentiation of various cell tyes
, inhibition of
.-:;:::-
Notchl signaling may induce differentiation. Consistent with this, treatment of 
Apcmin
mice displaying intestinal adenomas with GSI demonstrated a conversion from 
undifferentiated epithelial cell to a more differentiated goblet cell (van Es et aI.
, 2005).
However, it is predicted that following GSI treatment, the tall 
mice will not exhibit
persistent resistance; tall 
mice will likely reactivate Notchl signaling and relapse.
Consistent with this prediction, 100% of 
EJ1tTAINotch
IC cell leukemias relapse
following inactivation of Not ch by doxycycline treatment (Beverly et aI.
, 2005).
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Materials and Methods
Mice and Dox-regulated T -ALL cell line
F or the retroviral insertional mutagenesis screen, wild tye tall 
or mut tall
(R188G;R189G) neonates were injected with 50111 Moloney Murine Leukemia Virus (gift
from Dr. Rosenberg) and monitored daily for signs of disease. Kaplan-
Meier analysis
was performed comparing MoML V -infected mice to unnfected 
tall or mut tall
(R188G;R189G) mice.
To develop a dox-regulated Notch ALL line, a cohort of 
EJ1tTA/notch li mice
were aged and monitored for disease 
(EJ1tTAInotch mice gift from Dr. Capobianco).
To convert primary tuors to cultue EJ1tTA/notch /tall tumors were minced into a
single-cell suspension using frosted slides and cultued in RPMI with 
10% FBS , 1-
glutamine, Penicilin/Streptomycin, and 50l1M -mercaptoethanol. Primary 
tuor cells
were plated at three concentrations in a 6-well plate: 5 X 10
, 1 xl0 , and 2 x 10 cells per
well. Tumor cells are left undistubed for one week and subsequently fed 2-
3 times
weekly by the careful aspiration and addition of fresh media. When 
nonadherent cells
became confluent, they were transitioned to a 60mm dish
, and finally to a 10cm dish.
Inverse PCR and Southern Blot Analysis
Genomic DNA was isolated from MoML V - infected tall and 
mut tall (R188G;R189G)
tumors. One microgram of DNA was digested overnight with 
Pst!, heat-inactivated, and
ligated in a total volume of 600111 overnight at l6 The ligation was 
ethanol
precipitated and digested with 
Cia/. Following the CiaI 
digest, IPCR was performed
using the Long Template Expand Kit (Roche , Indianapolis , IN and primers to MoML V
LTR (5' CTT-GTG-GTC-TCG-CTG-TTC-CTT- ) and to the region adjacent to the 
Pst!
100
site within MoMLV (5' TTA-AGC-TAG-CTT-GCC-AAA-CCT-ACA-GGT-
). 
PCR
products were electrophoresed on a 1 % agarose gel, extracted, cloned into pCR4- 
TOPO
(Invitrogen, Carlsbad, CA), and sequenced.
Genomic DNA was extracted from MoML V -infected tall tuors and 
uninfected tall
tuors. l5 g was digested overnight with Eco RV (notchl cluster region I) or Asp 718
(notchl cluster region II) and electrophoresed on a 0.8% agarose- IX Tris-borate-EDTA
gel, and transferred to a nylon membrane. The membrane was then probed with a cDNA
probe corresponding to Notchl cluster region I or cluster region II as in (Feldman et aI.
2000).
Western Blot Analysis
Protein was isolated from MoML V -infected tuors, and wild type thymocytes using
RIP A buffer containing protease inhibitor tablets (Roche). Fifty micrograms of total
protein was resolved on a 7.5% SDS-P AGE gel, transferred to a nitrocellulose
membrane , and probed with polyclonal antibodies against full length Notchl 
(a gift from
Warren Pear), or an antibody specific for Notchl activated by cleavage at Val 1744
(#2421 , Cell Signaling Technology). Blots were stripped and reprobed with p-actin
(A544l , Sigma, St. Louis , MO) to control for equal loading.
Flow Cytometry
Following 24h, 48h, 72h doxycycline treatment g/ml), Notch ALL cell line was
stained with CD25- , CD4-FITC, or CD8-PE (pharmingen), fixed with 
paraformaldehyde, and analyzed by flow cytometr. For cell cycle analysis
, the cells
were fixed overnight with 70% ethanol, stained with propidium iodide and analyzed for
DNA content by flow cytometry. To test for sensitivity to y-secretase inhibitor treatment
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2x10 tall tuor cells were treated for 3 or 6 days with l M DAPT, fixed, and analyzed
for DNA content by PI staining.
Microarray Analysis
The dox-regulated Notch ALL cell line was treated with doxycycline g/ml) for
24h and RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA), and
purified using Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). RNA was hybridized to
Affymetrix Mouse Genome 430A 2.0 arrays (Affymetrix, Santa Clara, CA). Data sets
were analyzed using Rosetta Resolver, and Ingenuity softare programs and analyzed by
Manoj Bhasin (Dana Farber Cancer Institute).
RT-PCR
RNA was extracted using Trizol, and cDNA synthesized using Superscript First-Strand
Synthesis System (Invitrogen). Deltex, Hesl and Pre-Ta expression was assayed using
primers as in (Deftos et aI. , 2000).
Real-time PCR
RNA was extracted using Trizol, and cDNA synthesized using Superscript First-Strand
Synthesis System (Invitrogen). Primers to analyze c-myc expression (5' CTG-TTT-
GAA-GGC- TGG-A TT - TCC- T - and 5' -GTC-GTG-GCT -GTC- TGC-GG- 3' were
generated using Primer Express (Applied Biosystems). Relative quantities of mRNA
expression were analyzed using QRT-PCR in the presence of SYBR green (Applied
Biosystems ABI Prism 7300 Sequence Detection System, Applied Biosystems). For the
normalization Qf each sample the expression level of the gene was divided by that of p-
actin. The relative expression level was determined by comparing the normalized value
102
-acti ) to that in the reference sample (another normal tissue) included in the same
reaction.
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Figure 16. Notchl activated in MoMLV- infected mut tall tumors. A. Disease
acceleration in MoML V- infected mut tall transgenic mice. Kaplan Meier survival plot
of MoML V- infected mut tall transgenic mice. The cohort of mut tall 
mice consisted of
n=62 mice and the cohort of infected mice consisted of n=27 mice. MoML V -infected FVB
cohort consisted of n=10 (Feldman, Hampton et al. 2000) B. The notchl locus is a
common MoMLV- integration site in infected mut tall (RI88G;RI89G) tumors.
Genomic DNA from MoML V -infected tuors (lanes 1- 8) and from uninfected tall tuors
(lanes 9, 10) was digested with EcoRV and hybridized with a probe to cluster region I of
Notchl(Feldman, Hampton et al. 2000). C. Notchl activation in MoMLV-infected tall
and mut tall (RI88G;RI89G) tumors. Lysates from tuors with MoMLV integrations in
notchl (lanes 2 6) were probed with an anti-Notch 1 antibody. Lanes 1 3,4,7 are from
infected tuors with no detectable Notchl integrations and lane 8 contains wild type thymus.
D. Hesl and Deltex are expressed in tumors with MoMLV insertions in Notchl. Hesl
and Deltex expression was examined in wt and tall thymocytes and MoML V-infected
tumors with insertions in Notchl using RT-PCR. GAPDH was used as an internal control.
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Figure 17. Tumor cell lines from spontaneous tall tumors demonstrate Notchl activation
A) tall tumor cell lines express Hesl and Deltex. RT-PCR assaying Hesl , Deltex were
performed on seven tall cell lines. GAPDH was used as an internal control. B) Tall cell lines
exhibit sensitivity to y-secretase inhibitors. 72h treatment of tall cell lines with 1 M DAPT
induced a G arrest or apoptosis in tall cell lines C) DAPT treatment inhibits Notch
pathway in tall ALL lines. Notchl target genes , Hesl and Deltex , are assayed in tall
tumor cell lines by RT-PCR following18h and 24h DAPT treatment. GAPDH was used as 
internal control.
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Figure 18. Spontaneous tall tumors express cleaved Notchl. 
A) To examine tall tuor
cells for the presence of cleaved Notchl , tuor celllysates were separated by SDS-PAGE
electrophoresis , transferred to a membrane , and probed with antibodies to cleaved Notchl and
f)-actin. B) Tall tumor celllystes from mock-treated and DAPT - treated 
tall were separated
by SDS-P AGE electrophoresis, transferred to a membrane, and probed with antibodies to
cleaved Notchl .
ta/1 tumor cell lines
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Table 3: Notchl mutational analysis of tall, tall/heb+/- and
tall/ink4a/arf+/- tumors
Tumor Genotype5046 tall/+5151 tall/+5146 tall/+1444 tall/+5015 tall/+1330 tall/+5148 tall/+5188 tall/+1161 tall/+5145 tall/+4862 tall/+1469 tall 1011 tall/+135 tall/heb+/-756 tall/heb+/-720 tall/heb+ 8998 tall/heb+ 9450 tall/heb+/-9205 tall/heb+/-9306 tall/ heb+/-6839 tall/ heb+/-8283 tall/heb+ 3199 tall/ink4a/arf+ 2871 tall/ink4a1arf+/-3483 tall/ink4a/arf+/-2869 tall/ink4a/arf+/-3460 tall/ink4a/arf+/-3570 tall/ink4a/arf+/-2902 tall/ink4a/arf+/-3150 tall /ink4a/ arf+ 
Notchl status
het insertion 2420
het deletion 2492
het deletion 2489
het deletion 2360
het insertion 2361
wild type
wild type
het del 2360
Q)-stop 2419
het insertion 2361
het deletion 2488
het insertion 2361
Q)-stop 2419
het insertion
wild type
het insertion
Q)-stop 2296
het insertion 2420
L)-P 1668
wild type
het insertion 2360
wild type
het deletion 2426
wild type
het deletion 2490
wild type
Q)-stop 2382
wild type
het insertion 2474
het insertion/deletion 2356
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Figure 19. Mouse T-ALL cell line regulates Notch expression in a doxycycline-
responsive manner. A) Dox-regulated Notch ALL line regulates Notchl
protein levels in a doxycycline-dependent manner. Fift micrograms of protein
isolated from wild-type thymocytes, and dox-regulated T -ALL cell line were left
untreated or were treated with 2f!g/ml doxycycline. Celllysates were separated on a
5% SDS-PAGE gel and then probed with anti-Notchl antibody. B) H esl and
Deltex expression regulated in a dox-dependent manner. RT-PCR assaying Hesl
Deltex, and were performed in dox-regulated Notch T -ALL line, following mock
treatment or l8h and 24h dox (2f!g/ml) treatment. GAPDH was used as an internal
control.
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Figure 20. Notch provides proliferative and anti-apoptotic signal in dox-regulated
Notch T -ALL line. A) Inhibition of Notch signaling induces apoptosis. Following
72h dox treatment, cells were assayed for DNA content by staining with PI. Data is presented
graphically as mean:! standard deviation. B) Inhibition of Notch signaling induces G
arrest. Following 72h dox treatment, cells were assayed for DNA content by staning with PI.
Cell cycle profiles were obtained following electronically gating out subG cells and shown
graphically as mean:! stadard deviation.
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Figure 21. Constitutive Notch signaling alters expression of CD4 and IL2Ra. A) Notch
signaling represses CD4 expression. Following a 72h with doxycycline (2 g/ml) treatment
Dox-responsiveNotch ALL cells were stained with CD8-PE and CD4-FITC and analyzed by
flow cytometry. B) Constitutive Notch signaling induces CD25 expression. Dox-
responsive Notch cells were treated for 24 and 48 with g/ml Dox and assayed for CD25
expression levels by flow cytometry analysis.
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Table 4. Genes activated or repressed by Notchl in tuor cell line 
Description of gene (accession number)
Bel-XL (N_009743)
CD4 antigen (N - 013488)
B-cell1eukemia/lymphoma 6 (U41465)
Interferon gama receptor 1 (N - 010511)
RA-related orphan receptor gama (AJ132394)
T-cell receptor alpha chain (U95921)
Notch-regulated ankrin repeat protein (BI696369)
Notch gene homolog 3 (Drosophila) (NM 008716)
Notch gene homolog (Drosophila)1 (N 008714)
Interferon regulatory factor 4 (U34307)
Interferon activated gene 203 (M74124)
hair/enhancer-of-split related with YRW motif-like (BG6951 00)
Early growth restonse 1 (N_007913)
1L2 receptor alpha (AF054581)
pre T-cell antigen receptor alpha (NM _011195)
Interferon activated gene 202B (N_011940)
a disintegrin and metalloproteinase domain 19 (N _009616)
Nr2f2 (AI463873)
Deltex 1 homolog (Drosophila) (ABOI5422)
Interleuk 10 (N_OI0548)
hairy and enhancer of split 1 (BCOI8375)
Fold change
9.1
6.2
-4.5
-4.3
3.2
+3.
+3.
+3.3
+4.4
+4.
+5.3
+6.5
+6.
+8.
+9.
+10.
+11.
+13.
+13.
P value
1. 0E-
50E-9
3.42E-03
1.44E-
4.46E-13
1.66E 32
1.48E-3
1.3E-
88E-
3.39E-25
4.37E-02
90E-24
OOE+OO
OOE+OO
OOE+OO
OOE+OO
OOE+OO
69E-3
OOE+OO
6.49E-26
1.28E-
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Figure 22. Notch signaling regulates multiple Myc target genes. Ingenuity pathway
analysis demonstrates that constitutive Notch signaling alters the expression of multiple
Myc target genes. Shades of green indicated are either induced whereas shades of red
indicate genes are repressed.
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Table 5. Myc target genes altered upon conditional Notchl activation in mouse T-ALL cell line 
Symbol Gene Description Fold Change p-valueMi myc induced nuclear antigen +10.8 1.39E-
Fabp4 fatt acid binding protein 4 +5.4 2.00E-Adm adrenomedulin +5.4 2.10E-
Gadd45g growth arrest and DNA-damage 45 gamma +4. 1. 19E-Caldl caldesmon 1 +4.1 2.70E-Srm spermidine synthase +3.9 2.00E-Bcatl branched chain aminotransferase 1 +3.1 1.37E-Shmt serine hydroxymethyl transferase +2.3 2.50E-
Zbpl Z-DNA binding protein 1 - 8 1.50E-Folhl folate hydrolase -4.4 1.90E-
Adarbl adenosine deaminase, RNA-specific, Bl -5.4 3.30E-Ly6a lymphocyte antigen 6 complex, locus A - 9 8.50E-Ana2 anexin A2 - 8 5.90E-
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CHAPTER V
DISCUSSION
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Our laboratory has previously ilustrated that misexpression of Tall in thymocytes
results in thymocyte differentiation arrest in vivo and apoptosis 
in vitro (O'Neil et aI.
2001; O'Neil et aI. , 2004). However, the work presented in this thesis demonstrates an
additional fuction for Tall in cell cycle regulation in thymocytes (Chapter III). Using 
vivo bromodoxyuidine (BrdU)-incorporation analysis , we have shown premalignant tall
thymocytes exhbit a 70% increase of cells in S phase of the cell cycle. Therefore, in
addition to inducing a thymocyte differentiation arrest, Tall likely contributes to
leukemogenesis by inappropriately inducing S phase progression. The S phase induction
appears dependent of a fuctional DNA-binding domain, as mut tall (R188G;R189G)
mice do not exhibit the induction of S phase. This result suggests that a Tall/E47 or
Tall/Heb taget gene is responsible for the S phase induction. Microaray analysis
revealed activation of the Notch and Wnt receptor pathways in tall premalignant
thymocytes. Wnt5b and the Wnt taget gene, c-Myc , were upregulated in addition to
Notch target genes, Deltex, CD25, and Hesl. Since activation ofWnt and Notch
pathways have been suggested to induce proliferation and confer self-renewal capacity of
hematopoetic stem cells (Reya et aI. , 2003; Varnum-Finney et aI. , 2000), their induction
may contribute to Tall-mediated leukemogenesis.
Similar to the misexpression of other proliferative oncogenes Tall
inappropriately induces S-phase progression, and is associated with an increase in
apoptosis. In vivo-BrdU analysis of tall thymocytes demonstrates a 5- 10-fold increase in
subG cells , which appears dependent on p This increased apoptosis may explain
why although tall mice exhibit an increase in proliferation, they display an 2-fold
decrease in overall thymic cellularity (O' Neil et aI., 2004). Therefore, it is likely that
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mutation of apoptotic pathways would cooperate with tall in leukemogenesis; consistent
with this hypothesis tall/p53+/- mice display disease acceleration(Condorell et aI.
1996)
The ability of Tall to promote S-phase induction and apoptosis is reminiscent of
ectopic expression of c-Myc (Askew et aI. , 1991; Evan et aI. , 1992). Similar to the S
phase induction observed in tall thymocytes (Figure 12), in vivo BrdU-incorporation
analysis of Ell-Myc transgenic mice revealed a 2- to 4-fold increase in BrdU-positive
lymphocytes (Baudino et aI. , 2003). Interestingly, both Affymetrix micro array and real-
time PCR analysis performed on premalignant tall thymocytes demonstrate a modest
increase in c-Myc expression. Perhaps Tall indirectly promotes S phase induction and
the subsequent apoptosis by upregulating c-Myc expression. It will be interesting to
determine if Tall directly induces c-Myc expression, and future experiments should
include chromatin immUloprecipitation experiments to determine if Tall/E47 or
TalllHeb heterodimers can be detected at the E-boxes within the c-myc promoter.
Alternatively, E2a inhibition may also be causing the Myc induction. Consistent e2a-
deficient tumors exhibit amplification of chromosome 15 , which contains c-myc (Bain et
aI., 1997). Additionally, tall/lmol tuors show increased expression of c-Myc
(Chervinsky et aI. , 1999), and spectral karyotyping indicates 20% of tall tuors exhibit a
gain of chromosome 15 (unpublished data). Furhermore tall transgenic mice display
dramatically accelerated disease progression when crossed to casein kinase II (CK2)
transgenic mice (Kellher et aI. , 1996). CK2 is a serinelthreonine kinase that has been
shown to phosphorylate and stabilize c-Myc (Channavajhala and Seldin, 2002). Thus
multiple leukemic models exhibit modest induction of Myc , suggesting that this increased
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dosage of c-Myc may be important for leukemogenesis. Therefore, it is tempting to
hypothesiz that an additional role for Tall in leukemogenesis is the induction of c-
Myc.
Nonetheless , combined transgenic expression of Tall and c-Myc fail to cooperate in vivo
as no disease acceleration is observed 
inEJ1tTA/Myc/tall triple transgenic mouse (data
not shown). However, it remains possible that Tall and Myc cooperate in
leukemogenesis , as the experiment may be flawed since Myc and Tall 
expression may
not have been overlapping.
The lck- tall transgenic mIce develop leukemia with a long latency and
incomplete penetrance , indicating additional mutations are essential in leukemogenesis.
It has been previously shown that the deletion of the INK4A/ARF which encodes the
tumor suppressors p 16
INK4a and p l4ARF , is a common event in human TAL I-expressing
leukemic patients (Ferrando et aI., 2002). In addition, although the most frequent
mutation disrupting the INK4A/ARF 
allele is deletion of exon 2 , a common exon to both
p16INK4a and p14 , additional leukemic patients display the loss of either p14
ARF or
p16INK4A (Batova et aI. , 1997; Drexler, 1998; Gardie et aI. , 1998). Although, the overall
contribution of each tumor suppressor to T cell leukemogenesis remains unclear
, the
common viewpoint is loss of p 16
Ink4a is the importnt genetic mutation in
leukemogenesis. This thesis provides genetic evidence confirming Tall expression
cooperates with the loss of the 
ink4a/arf allele in vivo; tall/ink4a/arf+/- 
mice display
accelerated leukemogenesis with an increased penetrance (Chapter III). The cooperation
of Tall and loss of ink4a/arf allele indicates that disruption of Tall-mediated apoptosis
may be an important event in leukemogenesis. Consistent with this hypothesis
tall/p53+/- mice display disease acceleration(Condorell et aI. , 1996).
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A subset of tall/ink4a/arf+/- tuors undergoes LOH, as indicated by loss of the
shared exon 2, while another subset demonstrates evidence of 
pl6ink4A promoter
methylation. Although this analysis implicates that loss of either p 16
Ink4a or p 19Ar may
cooperate with Tall , their relative contribution remained unclear. To determine whether
Tall preferentially cooperates with loss of p l6
Ink4a or p 19Arf, we generated both
tall/p16ink4a
+/- 
and tall/pl~rf+/- mice, and observed similar disease acceleration
indicating Tall cooperates with loss of either p16
k4a or p19
. This demonstrates for
the first time that the loss ofp19
Ar contrbutes to Tall-mediated leukemogenesis.
The cooperation of Tall with the loss of p 19
Arf is consistent with Tall-induced
proliferation and apoptosis. Similar to the mechanism delineated in Ej.-Myc-induced
lymphoma (Eischen et aI., 1999), disruption of the p19
arf Mdm2-p53 pathway in tall
thymocytes may prevent the Tall-mediated apoptosis, thereby allowing pre-leukemic
clones to surive. Conversely, the cooperation of Tall with loss of p16
Ink4a reflects the
common loss ofp16INK4A observed in human leukemias. This cooperation may be due to
increased proliferative signal or effects of p 16Ink4a loss on senescence.
Additionally, my thesis research has identified Notchl activation as a common
secondary event that occurs during leukemogenesis. By performing RIM, we determined
activation of the Notchl signaling pathway may cooperate with Tall in leukemogenesis
(Chapter IV). Specifically, 32% of MoMLV- infected mut tall(Rl88G;R189G) tumors
exhibit MoML V integrations between exons 22-26 of notchl presumably creating an
allele capable of ligand-independent signaling. Conversely, MoML V - infected mut tall
(R188G;R189G) tuors lacked MoML V integrations in the 3' of notchl resulting in the
loss of the negative-regulatory PEST domain, and the subsequent enhanced stability of
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Notch . The majority of tuors exhibiting notchl integrations continue to express
Notchl , Deltex, and Hesl , indicating the tuors remain 
dependent of Notch 1 signaling.
Significantly, a study revealed over 50% of human T-ALL patients exhibit
mutations in the HD and PEST domains of 
NOTCHl (Weng et aI. , 2004). In fact, 43% of
ALL patients contain mutations in the HD domain, which 
are hypothesized to
destabilze the NEC/NTM interaction and confer greater susceptibility to 
y-secretase
cleavage (Figure 23) (Weng et aI., 2004). An additional 30% of T -ALL patients
demonstrate an insertion/deletion into the PEST domain. Of these patients
, 18% contain
both lI and PEST mutations together in cis (Weng et aI. , 2004).
Concurent with this clinical finding, we demonstrate spontaneous 
tall tuors
also exhibit frequent Notchl activation. In fact, the vast majority of 
tall tumor cell lines
express cleaved Notchl , and continue to express Notchl target genes
, Hesl and Deltex
indicating the tuors remain dependent on Notchl 
signaling. Furhermore tall tuors
exhibit a Gl arest and/or apoptosis following treatment with y-secretase inhibitors (GSI).
Consistent with the widespread Notchl activation in 
tall tuors , we observe mutations
in the HD andlor PEST domains of notchl in 25/35 (71%) of tall 
tumors examined.
However, no tall tuors exhibit mutations in notch2, 3, or, 4, suggesting 
Notchl
activation may preferentially contribute to Tall-mediated leukemogenesis. Interestingly,
transgenic mice expressing both BHLHBI and LM02 , two proteins that 
inhibit E2a
. fuction, develop T cell tumors exhibiting Notchl activation, as revealed by 
GSI-
sensitivity and notchl mutations (Lin et aI. , 2005). However, lymphomas arising in mice
deficient for various combinations of rag2, H2AX or p53-
/- 
demonstrate a greatly
reduced frequency of Notchl activation (O'
Neil, unpublished data). Additional
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mutational analysis for other transgenic mouse models that display E2a inhibition should
be performed, but together these data suggests that inhbition of E2a may cooperate with
Notch activation in leukemogenesis.
Although the vast majority of the tall tuors exhibit Notchl activation, we stil
do not understand the signal Notchl provides leukemic cells. To try to elucidate this
signal, I generated a doxycycline-responsive Notch cell line. Treatment of the dox-
responsive Notch cell line resulted in a decrease in the expression of Notch 1 and Notch
target genes as early as 24h following dox treatment. Additionally, a 72h dox treatment
induces both a G arest and an accumulation of SUbGI cells , indicating that Notch
providing both a proliferative and anti-apoptotic signal. Performing gene expression
profiing revealed the dox-mediated regulation of numerous Notchl 
target genes,
including: Hesl , Deltex , CD25 , Nrarp, ILI0 , IRF4 , Egrl , and ADAM 19. This analysis
also provides a list of new Notchl target genes, which are curently undergoing fuher
validation. Significantly, we observe the upregulation of c-Myc in the dox-responsive
cell line , and we have preliminary evidence of parial rescue following ectopic expression
of c-Myc. However, it is unikely that one gene wil fully rescue Notch induced effects.
We are in the process of performing additional micro array analysis on GSI-treated tall
tumor cell lines. Since GSI treatment is not Notch-specific, the comparison of gene
profiing from GSI-treated tuors to the dox-responsive cell line wil allow us to
establish which targets in the GSI-microarray are Notch-specific. 
Additionally, these
comparsons wil allow us to elucidate what genes are globally affected by Notch
activation in leukemia. Although this strategy wil likely iluminate important Notch
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targets in leukemogenesis, it is predicted that in other malignancies , the Notch targets
will vastly differ.
In summary, my thesis work has revealed a novel fuction for Tall in leukemia;
expression of Tall in thymoyctes promotes an S phase induction and is associated with
an increase in apoptosis. Tall transgenic mice develop disease with a long latency and
incomplete penetrance indicating additional genetic events are essential for
leukemogenesis. In my thesis work I have identified two secondar mutations that
cooperate with Tall: the loss of either p 16Ink4a or p 19
Arf
, and the activation of the Notchl
signaling pathway. In the process of identifying cooperating mutations, I modified the
tall transgenic mouse model to more closely resemble human T-ALL. Tall/ink/arf+/-
mice exhibit the two most common mutations observed in human T -ALL , and develop
leukemia with a complete penetrance. Therefore, this mouse model is amenable to
testing potential therapeutic compounds, such as GSI or HDAC inhibitors in vivo.
Additionally, it can be used to develop therapeutic agents for T-ALL patients displaying
both TALI overexpression and loss of INK4A/ARF a specific subset of patients given a
poor prognoSIS.
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Figure 24. Schematic of NOTCHl mutations observed in T -ALL. Domains of NOTCHI
exhibiting frequent mutations in T-ALL are identified (red). HD mutations lead to increased
NOTCW production due to increased susceptibility to y-secretae cleavage. PEST mutations
result in PEST deletion and increase NOTCH stability. Red arrow signifies site ofy-secretase
cleavage
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Figure 24. Proposed model of Tall-mediated leukemogenesis. We have previously
demonstrated that Tall inhbits E2a fuction and induces a thymocyte differentiation arest.
This thesis demonstrates that Tall additionally promotes an S phase induction, and 
associated with an increase in thymocyte apoptosis. Microarray analysis suggests the Wnt and
Notch receptor pathways may contrbute to the S phase induction. We demonstrate that loss of
ink4a/arf locus cooperates with Tall in leukemogenesis , suggesting that disruption of this
Tall-mediated apoptosis is an important step in leukemogenesis. Finally, we demonstrate
another important genetic event in Tall-mediated leukemogenesis is Notchl activation.
Dotted lines indicate parts of the pathway that require additional investigation.
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Supplemental Data Genes Activated or Repressed in 
ta/1 thymocytes
Primary
Sequence
Fold
Name Se uence Descri tion
Accession # Chan e -value
Rsdr1-pending
retinal short-chain dehydrogenase/reductase 011303 22. 99E-
Irf6 interferon regulatory factor 6
016851 19.48 09E-
Cldn4 claudin 4
009903 15. 2.43E-
Smoc1-pending secreted modular calcium-binding protein 1
022316 12. 20E-
Klc3 kinesin light chain 3
BC017147 12. 56E-
Gtf2h4 general transcription factor IIH, polypeptide 4 BE457600
00205
SIc7a11
solute carrier family 7 (cationic amino acid 011990 00E-
transporter, y+ system), member 11
Plxnd 1 Plexin D1
BC019530 01 E-
Idb3 inhibitor of DNA binding 3
008321
Olig3 oligodendrocyte transcription factor 3 053008
00049
Pip5k1a
phosphatidyl i nos itol- phos phate 5-ki nase, 008846 00134
e 1a
Prodh proline dehydrogenase 011172
01 E-
Tnfaip9 tumor necrosis factor, alpha- induced protein 9 054098
00184
Ntn1 netrin 1
BI143915 18E-
Art1 ADP-ribosyltransferase 1
U31510 2.42E-
Taa1 tumor-associated antigen 1 009310
9.44E-
Insl5 insulin-like 5
011831 11 E-
Atp1 b1
ATPase, Na+/K+ transporting, beta 009721 6.45 27E-
e tide
Atp1 b1
ATPase , Na+/K+ transporting, beta A V152334
e tide
Tgfb1 i4 TGF beta 1 induced transcript 4 AU016382
22E-
F13a1 coagulation factor XIII , A 1 subunit 028784
Zdhhc14 zinc finger, DHHC domain containing 14 BC021423
92E-
T cra- V8 T-cell receptor alpha , variable 8 M31649
00033
Zdhhc14 ESTs AV223474
67E-
Igh-VJ558 immunoglobulin heavy chain (J558 family) 134051
08E-
Lox Iysyloxidase BB820958
00325
Tilz1b
TSC22-related inducible leucine zipper 1 b AF201285 85E-
Tilz1b
Igh-VJ558 immunoglobulin heavy chain (J558 family) BC019425 5.49
1.41 E-
Zdhhc14 ESTs BB318221
5.42
Cd5 CD5 antigen 007650
Zdhhc14 ESTs AV361868
79E-
Tgfb1i4 TGF beta 1 induced transcript 4 BB357514
26E-
Centd 1 ESTs AV375176
69E-
Tec cytoplasmic tyrosine kinase , Dscr28C related 013689
87E-
Map4k5 MAP kinase kinase kinase kinase 5 BC002309
81 E-
Vamp1 Mus musculus adult male cerebellum cDNA AK018783
71 E-
Atp1 b1
ATPase , Na+/K+ transporting, beta BC027319 71 E-
e tide
Egr2 early growth response 2 X06746
88E-
157
114ra interleukin 4 receptor, alpha AF000304 34E-
Tns tensin NM 027884 0007
Rag2 recombination activating gene 2 NM 009020 05E-
Mmp14
matrix metalloproteinase 14 (membrane- 008608 37E-
inserted)
Igh-VJ558 Mus 10 day old male pancreas cDNA AK007826 08E-
Cacna1c CA channel
, voltage-dependent, L type , alpha 009781 74E-
Tgfb1 i4 TGF beta 1 induced transcript 4 AU016382 20E-
P2rx1
purinergic receptor P2X , ligand-gated ion 008771 55E-
channel 1 
114ra interleukin 4 receptor, alpha NM 010557 5.47E-
Ankrd6 ankyrin repeat domain 6 BM 199504 4.47 74E-
Gtf2h4 general transcription factor IIH, polypeptide 4 NM 010364 4.43 64E-
Cd6 CD6 antigen U12434 4.42
P2rx1
Mus musculus 10 day old male pancreas AK007650 -4. 35E-
cDNA
Epha2 Eph receptor A2 NM 010139 19E-
Cxxc5 Mus musculus adult male testis cDNA AK015150 31 E-
Bcl21 Bcl2-like NM 009743 36E-
Atp9a ATPase , class II, type 9A NM 015731 00005
Dusp6 dual specificity phosphatase 6 NM 026268 06E-
Map4k5 H3060B09-3 NIA Mouse 15K cDNA Clone Set BG067961 78E-
H2-T17 histocompatibilty 2 , T region locus 17 AW822416 58E-
Zdhhc14 ESTs BB544336 10E-
Sp011 sporulation protein SP011 homolog- 012046 15E-cerevisiae
Fos FBJ osteosarcoma oncogene A V026617 0006
Gtf2h4 general transcription factor IIH, polypeptide 4 BB168668 80E-
Cxxc5 CXXC finger 5 NM 133687 08E-
Pacsin1 protein kinase C and casein kinase substrate BI731319 00359in neurons 
Egr1 early growth response NM 007913 32E-
H1fO H1 histone family, member 0 NM 008197 10E-
Sytl2 synaptotagmin- like 2 NM 031394 82E-
cd4 mutant T-cell surface glycoprotein CD4 U75219 3.48 03E-
Nr4a1
nuclear receptor subfamily 4 , group A 010444 3.47 16E-
member 
XT- xylosyltransferase II (XT- II gene). AJ291751 3.47 00012
Bcl21 Bcl2-like U10100 3.44 26E-
Wdfy2 WD repeat and FYVE domain containing 2 BB794924 20E-
Mad111 mitotic arrest deficient 1-like 1 BC010702 15E-
Nab2 Ngfi-A binding protein 2 N M 008668 60E-
H6pd hexose- phosphate dehydrogenase (glucose BC027358 10E-dehyd rogenase)
Syngr1 synaptogyrin 1 NM 009303 00113
Ccrk cell cycle related kinase NM 053180 98E-
Grca gene rich cluster , A gene NM 013533 18E-
Glcci1 ESTs, Highly similar to AC006042 AA 152997 84E-
Bach2 BTB and CNC homology 2 AW553304 1.41E-
158
H1fO H1 histone family, member 0
BC003830 01 E-
Mox2 antigen identified by antibody MRC OX- AF004023
96E-
Pfn2 profilin 2
019410 96E-
Skir ski/sno related
U36203 00002
Img integral membrane glycoprotein 008377
75E-
St6gal1 H3152A02-3 NIA Mouse 15K cONA Clone BG075800
58E-
Bcl6 B-ceilleukemia/lymphoma 6
U41465 11 E-
Rorc RAR-related orphan receptor gamma AJ 132394
57E-
Nr1d2
nuclear receptor subfamily 1 , group 0 011584 75E-
member 2
Acvrl1 activin A receptor, type II-like 1 BC014291
00056
Emid1 EMI domain containing 1 080595
00062
Ephx1 epoxide hydrolase 1 , microsomal 010145
63E-
Prep prolyl endopeptidase 011156
33E-
Atp9a ATPase, class II , type 9A AF011336
00203
Rgs 10 regulator of G-protein signallng 10 026418
21 E-
Car2 carbonic anhydrase 2 009801
18E-
Cd4 C04 antigen 013488
31 E-
N30.7TCRA
Mouse mRNA for T-cell receptor insulin (A- U95921 24E-
chain) reactive alpha chain VJC
SIc37a2
solute carrier family 37 (glycerol- phosphate BC022752 12E-
transporter). member 2
Capn3 calpain 3 AF127766
13E-
Zfp36 zinc finger protein 36 X14678
90E-
Mef2a myocyte enhancer factor 2A BC019116
00476
Neu3 neuraminidase 3 016720
21E-
Idb2 inhibitor of DNA binding 2 010496
80E-
Img integral membrane glycoprotein AV174595
76E-
Itm2a integral membrane protein 2A BI966443
Tdag T-cell death associated gene 009344
04E-
Gsta4 glutathione S-transferase , alpha 4 010357
33E-
Vamp1 Mus musculus adult male cerebellum cDNA AK018783
29E-
Nphs2 nephrosis 2 homolog, podocin (human) 130456 0002
Chst10 ESTs BB549997
54E-
Gem GTP binding protein U10551
00002
SIco3a1
solute carrier organic anion transporter family, 023908 80E-
3a1
Pkcz protein kinase C, zeta 008860
00358
Tnfrsf4 tumor necrosis factor receptor superfamily 4 011659
91 E-
Tcra
T -cell receptor insulin -reactive alpha chain U07662 64E-
VJC
Hs6st1 heparan sulfate 6-0-sulfotransferase 1 015818
02E-
Clk3 CDC-like kinase 3 AF033565
58E-
117r interleukin 7 receptor AI573431
2.42E-
putative
Mouse mRNA for T-cell receptor insulin (A- X01134 22E-
chain) reactive alpha chain VJC
Rhoip3-pending Rho interacting protein 3 U73200
51 E-
Hbb-bh1 hemoglobin Z , beta- like embryonic chain AV024771
60E-
Ldh2 lactate dehydrogenase 2 . B chain 008492 2.44E-
159
..,
Tnfaip3 tumor necrosis factor, alpha- induced protein 3 NM 009397
55E-
Mtss 1 metastasis suppressor 1
8C024131 4.47E-
IL2 receptor Mus musculus interleukin 2 receptor mRNA AF054581
52E-
Pfc RIKEN cDNA 1500032P08 gene 88800282
00308
Hsp105 heat shock protein 105 81499717
01 E-
Sdh1 sorbitol dehydrogenase AV253518
00002
Depdc6 DEP domain containing 6 8C004 774
00045
Sas sarcoma amplified sequence NM 025982
21 E-
Papss2 ESTs 8F786072
00008
Cxcr6 chemokine (C- C motif) receptor 6 NM 030712 09E-
Tagln2 transgelin AV212626
88E-
Pdgfrb platelet derived growth factor receptor , beta AA499047
0015
Gja1 ESTs 88039269 53E-
Ly6c lymphocyte antigen 6 complex , locus C NM 010741
56E-
Comtd 1 Mus 10 day old male pancreas cDNA AK007659
00218
Dtx1 deltex 1 homolog (Drosophila) A8015422 92E-
Hspa8 Mus musculus adult male lung cDNA AK004608
83E-
Myo6 ESTs 8E 133806
00005
Myo1f myosin If NM 008660
00053
Gm2a GM2 ganglioside activator protein 8C004651
96E-
Angptl2
602356479F1 NCI CGAP _Mam1 cDNA 8G244279 15E-
clone
Wwox
Mus musculus adult male pituitary gland AK019911 00072
cDNA
Cdk6 cyclin-dependent kinase 6 NM 009873
00216
Evi5 ecotropic viral integration site 5 AI255184
0046
Hsp70- heat shock protein , 70 kDa 1 M12573
59E-
Eef2k eukaryotic elongation factor-2 kinase 8C003433
00011
Ephb2 ESTs AV221401
51 E-
111 rrp interleukin 1 receptor related protein NM 008365
17E-
Fcna ficolin A NM 007995
51 E-
Trf transferrin AF440692
28E-
Gig1 glucocorticoid- induced gene 1 mRNA AW413620
14E-
LOC58860 disintegrin metalloprotease (decysin) NM 021475 00009
Ccl6 chemokine (C-C motif) ligand 6 8C002073 98E-
Ifi202b interferon activated gene 2028 NM 011940
4.46E-
Myo6 myosin VI NM 008662 4.42
00013
D130038821Rik RIKEN cDNA D130038821 gene 8C025514
66E-
Fcgr3 Fc receptor, IgG , low affinity III NM 010188
0002
Scya9 small inducible cytokine A9 AF128196
00042
Gja1 ESTs 88142324 00008
Scd1 stearoyl-Coenzyme A desaturase1 NM 009127 5.40
00047
Pla2g7 Mus musculus adult male cerebellum cDNA AK005158 5.43
96E-
Api6 apoptosis inhibitory 6 NM 009690 5.45
00317
Alox15 arachidonate 15-lipoxygenase L34570 5.46
89E-
8aat bile acid-
Coenzyme A dehydrogenase: amino 007519 00369
acid n-acyltransferase
Cd38 ESTs 88256012
00288
complement component 4 (within H-2S) NM 009780 88E-
160
010Ertd322e
H3047G06-3 NIA Mouse 15K cONA Clone 8G066857 00325
Set
C1nh complement component 1 inhibitor
NM 009776 00004
Fn1 fibronectin 1
8C004724 53E-
Gypa glycophorin A
NM 010369 00303
Ctla2a cytotoxic T Ivmphocvte-associated protein 2 a NM 007796
7.45E-
Eraf erythroid associated factor NM 133245
94E-
Pbx3 pre 8-celileukemia transcription factor 3 NM 016768
00007
Pgcp BB468025 RIKEN full- length enriched
B8468025 00021
Zac1
zinc finger protein regulator of apoptosis and AF147785 08E-
cell cycle arrest
Rnf128 Mus musculus adult male liver cONA
AK004847 00009
coagulation factor V NM 007976 00021
LOC58209
similar to megakaryocyte stim. factor 021400 79E-
precursor
Wnt5b wingless-related MMTV integration site 58 NM 009525
00037
Fgfr1 fibroblast growth factor receptor 1 M33760
00068
Eomes ESTs B8128925
10. 00009
Planh2 plasminogen activator inhibitor , type \I NM 011111
10. 09E-
Fizz1-pending found in inflammatory zone 1 NM 020509
10.
Oyrk3
d ual-s pecificity tyrosine-(Y)-phosphorylation BC006704 10. 00252
regulated kinase 3
Ptpn 13 protein tyrosine phosphatase , non-receptor 13 BM236743
10. 00003
Snrpn small nuclear ribonucleoprotein N AI836293
11. 00068
M32486 Mouse 19.5 mRNA NM 019631
11. 7.47E-
SIc4a1
solute carrier family 4-anion exchanger B8448377 12. 1.43E-
member 1
Slc22a3 solute carrier family 22 , member 3 NM 011395
15. 88E-
Saa3 serum amyloid A 3 NM 011315
15. 00215
Ssb4 SPRY domain-containing SOCS box 4 BC023083
15. 77E-
Snurf SNRPN upstream reading frame NM 033174
16. 92E-
Ly84 lymphocyte antigen 84 013695
18.45 31 E-
Chi313 chitinase 3- like 3
NM 009892 28.
Chi314 chitinase 3- like 4
A Y065557 33.
Ril-pending reversion induced LlM gene NM 019417
41. 79E-
161
Supplemental Data 2: Genes activated or repressed by Notch in 
doxycycline-
regulated T -ALL cell line 
Primary
Sequence
Fold
Name Se uence Oescri tion Publid 10
chan e -value
Soat1 sterol O-acyltransferase 
BG064396 18. 76E-
Ccrk cell cycle related kinase
053180 15. 00087
SIamf1
signaling lymphocytic activation molecule BB132695 14. 1.41 E-
family member 1
Mxd4 Max dimerization protein 4 BE291523
13. 00031
Ccr9 chemokine (C-C motif) receptor 9 009913 10.
Ly6c lymphocyte antigen 6 complex , locus C
010741 10. 24E-
T cfcp213 transcription factor CP2-like 3 AF411213
00445
Rora RAR-related orphan receptor alpha
013646 00244
Gats opposite strand transcription unit to Stag3 BC026208
00046
Fprl1 formyl peptide receptor-like 1
008042 00177
Papss2
phosphoadenosine 5' phosphosulfate BF786072 00064
synthase 2
Epsti1 epithelial stromal interaction 1 (breast) AK017174
00452
Rora RAR-related orphan receptor alpha BI660199
95E-
Kctd12
potassium channel tetramerisation domain BM220945 82E-
containing 12
Cd4 C04 antigen 013488
50E-
Itk IL2-inducible T-cell kinase L 10628
38E-
Ly6a lymphocyte antigen 6 complex , locus A BC002070
59E-
Tnfrsf6
tumor necrosis factor receptor superfamily, 007987 00405
member 6
Ccr9 chemokine (C-C motif) receptor 9 AJ131357
Plec1 plectin 1
AW123286 5.43 00301
0lx1 distal- less homeobox 1 ect assay
010053 81 E-
Tktl1 transketolase-like 1 C79967
00001
Ctsl cathepsin L
J02583
Tktl1 transketolase-like 1 031379
4.49 09E-
Igsf4a immunoglobulin superfamily, member 4A 018770
4.48 00003
Serpini1
serine (or cysteine) proteinase inhibitor 009250 4.40 25E-
clade I , member 
Ifngr1 interferon gamma receptor 
010511 1.44E-
Glcci1 glucocorticoid induced transcript AA 152997
Grca gene rich cluster, A gene
013533 01E
Trp53inp2
tumor protein p53 inducible nuclear protein AK003956 00442
Mtap7 microtubule-associated protein 7
008635 00154
Utrn utrophin
X83506 0015
Satb1 special AT-rich sequence binding protein BG092481
09E-
Serpini1
Mus musculus serine (or cysteine) 009250 01E-
proteinase inhibitor, clade I , member 1
Cd200 Cd200 antigen AF004023
79E-
Itgam integrin alpha M
008401 26E-
162
Rorc RAR-related orphan receptor gamma AJ 132394
4.46E-
Ssbp2 single-stranded DNA binding protein 2 A Y037837
1.45E-
Fbxo32 box only protein 32 AF441120
00331
Hmgcs2
hydroxy-3-methylglutaryl-Coenzyme A BC014714 8. 1 OE-28 
synthase 2
Ifngr2 interferon gamma receptor 2 BF537076
00022
Rapgef4
Rap guanine nucleotide exchange factor AK004874 3.46 22E-
(GEF) 4
Fbxl12 box and leucine-rich repeat protein 12 NM 013911
3.45
Lztfl1 leucine zipper transcription factor-like 1 NM 033322
55E-
Socs1 suppressor of cytokine signaling AB000710
00021
Ltb Iymphotoxin B NM 008518
11E-
Tcra T-cell receptor alpha chain U95921
66E-
Prkd2 protein kinase D2 AW557946
03E-
Cpt1 a carnitine palmitoyltransferase 1 a , liver BB021753
00181
Satb 1 special AT-rich sequence bind ing protein 1 AV172776
Ms4a6b
membrane-spanning 4-domains , subfamily 027209 56E-
, member 6B
Lrrfip1
leucine rich repeat (in FLII) interacting 008515 0028
protein 1
Lgals1 lectin , galactose binding, soluble AI642438
Ypel1 yippee-like 1 (Drosophila) NM 023249 23E-
Prkd2 protein kinase D2 BB204677
29E-
Lgals 1 lectin , galactose binding, soluble 1 NM 008495
20E-
Zdhhc2 zinc finger, DHHC domain containing 2 BB224658
00045
Hfe hemochromatosis AJ306425
26E-
Emp1 epithelial membrane protein U25633
58E-
Sdccag8 serologically defined colon cancer antigen 8 AA690806
00272
Ypel3 yippee-like 3 (Drosophila) BI660196 90E-
pycard PYD and CARD domain containing BG084230
00424
Hist1h1c histone 1 , H1c BB533903
85E-
Tec cytoplasmic tyrosine kinase
, Dscr28C 013689 85E-
related (Drosophila)
Tcra T-cell receptor alpha chain X01134
1 . 17E-
Tcra T-cell receptor alpha chain U07662
61 E-
Cd52 CD52 antigen NM 013706
89E-
Rnasel ribonuclease L (2'
, 5'-oligoisoadenylate BF714880 17E-
synthetase-dependent)
Foxb1 forkhead box B U90538
74E-
Plxdc1 plexin domain containing 1 AF378760
75E-
Mr1
major histocompatibility complex , class 1- BB21 0729 60E-
related
Rab3d RAB3D, member RAS oncogene family BB349707
0005
Itga4 integrin alpha 4 NM 010576
98E-
Cd47 CD47 antigen NM 010581
10E-
Gpr65 protein coupled receptor 65 NM 008152
95E-
Ipo4 importin 4 NM 024267
07E-
Myc myelocytomatosis oncogene BC006728
1.43E-
163
SIc19a1
solute carrier family 19 (sodium/hydrogen 031196 00228
exchanger), member 
SIc12a2 solute carrier family 12 , member 2 BG069505
00022
Pla2g 12a phospholipase A2 , group XIIA A Y007382
91 E-
Rpo1- RNA polymerase 1- BB729239
38E-
Nedd4 Neural precursor cell expressed BG073415
04E-
developmentally down-regulted gene 4
Smyd2 SET and MYNO domain containing 2 BC023119
19E-
Ptpn13
protein tyrosine phosphatase, non-receptor BM236743 4.44E-
type 13
Wdr4 WO repeat domain 4 BE854862
00029
Shmt1
serine hydroxymethyl transferase 1 AF237702 63E-
soluble
Chchd4
coiled-coil-helix-coiled-coil-helix domain 133928 73E-
containing 4
Rpo1- RNA polymerase 1- NM 009086
19E-
Nrarp Notch-regulated ankyrin repeat protein BI696369
15E-
Grwd1 glutamate-rich WO repeat containing BB251524
66E-
sialyltransferase 7 ((alpha-
Siat7d
acetylneuraminyl 2 betagalactosyl- 1 , 3)- AK007601 11 E-
acetyl galactosaminide alpha-
sialyltransferase) 0"
Nr4a1
nuclear receptor subfamily 4 , group A 010444 25E-
member 1
Thbs2 thrombospondin 2 011581
05E-
Gja1 gap junction membrane channel protein BB039269 12E-
alpha 1
Nfkbiz
nuclear factor of kappa light polypeptide AB026551 00065
gene enhancer in B-cells inhibitor, zeta
Fbxo31 box only protein 31 133765
00001
Tpbg trophoblast glycoprotein BQ177165 00036
Grwd1 glutamate-rich WO repeat containing BB251524
99E-
Gsto1 glutathione S-transferase omega 010362
96E-
Slc11a2 solute carrier family 11 (proton-coupled BG065264 81E-divalent metal ion transporters), member 2
Ssb4 SPRY domain-containing sacs box BC023083
54E-
Cyb561 cytochrome b-561 BC006732
00001
Gadd45b
growth arrest and DNA-dam age- inducible AI323528 00232
45 beta
Stc1 stanniocalcin 1 BQ032752 89E-
Gas5 growth arrest specific 5 BI650268
76E-
Ifrd2
interferon-related developmental regulator BB540964 91 E-
Mdn1 midasin homolog (yeast) 133874 5.48E-
Rgs3 regulator of G-protein signaling 3 AF350047
00007
Sgtb
small glutamine-rich tetratricopeptide BC017611 0001
repeat (TPR)-containing, beta
Rnu3ip2
RNA, U3 small nucleolar interacting protein BC014703 70E-
164
Endog endonuclease G AV104666 00084
Stc2 stanniocalcin 2 AF031 035 1.42E-
Notch1 Notch gene homolog 1 (Drosophila) NM 008714 88E-
Zbtb16 Zinc finger and BTB domain containing 16 AA419994 00025
Hrb HIV-1 Rev binding protein BB130716 66E-
Notch3 Notch gene homolog 3 (Drosophila) NM 008716 13E-
Ppan peter pan homolog (Drosophila) BC014688 75E-
Mettl1 methyltransferase-like 1 NM 010792 4.44E-
Lef1 lymphoid enhancer binding factor NM 010703
Shmt1
serine hydroxymethyl transferase 009171 25E-
soluble
Rsu1 Mus musculus Ras suppressor protein NM 009105 12E-
Dsp Desmoplakin BC026631 51 E
Nefh neurofilament, heavy polypeptide M35131
00172
Srm spermidine synthase NM 009272 76E-41
Frmd4b FERM domain containing 4B BG067753 00005
1131 ra interleukin 31 receptor A AB083111 89E-
Hrb HIV-1 Rev binding protein BQ174030
Smyd5 SET and MYND domain containing 5 BF160651 00014
Hk2 hexokinase 2 NM 013820 21 E-
Comtd 1
catechol-O-methyltransferase domain AK007659 4.41 00008
containing 1
Itgb5 integrin beta 5 BB543646 4.41 00005
Kai1
kangai 1 (suppression of tumorigenicity 6 007656 4.46
prostate)
Heyl
hairy/enhancer-of-split related with YRPW BB310549 00035
motif-like
Irf4 interferon regulatory factor 4 U34307 39E-
Heyl
hairy/enhancer-of-split related with YRPW BG695100 99E-
motif-like
lltifb
interleukin 10-related T cell-derived AJ249492
inducible factor beta /1 interleukin 22
Hrb HIV- 1 Rev binding protein BB130716
Cited1
Cbp/p300- interacting transactivator with U65091 36E-
Glu/Asp-rich carboxy-terminal domain 1
Myl4 myosin , light polypeptide 4 010858 26E-
Frmd4b FERM domain containing 4B BB009122 68E-
Gadd45g growth arrest and DNA-
damage-inducible
AK007410 19E-
45 gamma
Egr1 early growth response 007913
Chst2 carbohydrate sulfotransferase 2 018763 5.48 00013
Plce1 phospholipase C , epsilon 1 A V306884 00374
Cd2 CD2 antigen 013486 03E-
Mef2b myocyte enhancer factor 2B D87833 00007
Nab2 Mus musculus Ngfi-A binding protein 2 008668 97E-
Lamb1- laminin B1 subunit 1 BG970109 00311
ptcra pre T-cell antigen receptor alpha 011195
Ifi202b interferon activated gene 202B 011940
165
Gfra 1
glial cell line derived neurotrophic factor BE534815 00183
family receptor alpha 1
Mafb v-maf musculoaponeurotic fibrosarcoma AW412521 00074oncogene family, protein B (avian)
112ra interleukin 2 receptor, alpha chain AF054581
Adam 19 Mus musculus a disintegrin and 009616 10.metalloproteinase domain 19 (meltrin beta)
Mina myc induced nuclear antigen AK013451 10. 00139
Nr2f2 nuclear receptor subfamily 2
, group F, AI463873 11. 74E-
member 2
Dtx1 deltex 1 homolog (Drosophila) AB015422 11.
Cntnap2 contactin associated protein-like 2 AU079588 11. 8.42E-
Cdh1 cadherin 1 009864 13. 69E-
Esm1 endothelial cell-specific molecule BC020038 17. 2.46E-
Hes1 hairy and enhancer of split 1 (Drosophila) BC018375 19. 28E-
1110 interleukin 10 010548 19. 6.49E-
166
